<a id='783375b4-4d73-4aad-83e3-89f1acf46827'></a>

APPENDIX 5-1. Sample Enteral Nutrition Plan for Pediatric and Infant Patients

<a id='c566ab2d-bf2a-428c-9014-548b76d39e69'></a>

## Pediatric Patient

Patient: 8-year-old female with a history of complex congenital heart disease. She has a gastrostomy tube in place that has not been used for fluid or nutrition in several years. No malnutrition noted on admission for cardiac surgery, and parental report is that patient ate 3 meals per day plus snacks. She included all food groups and consumed portions sizes similar to her peers, although parents could not quantify. Beverages commonly consumed included water and 1% milk. No known food allergies or intolerance. When a gastrostomy tube was used in the past, a standard milk protein-based pediatric formula was tolerated. Postoperative course was complicated by bleeding, extracorporeal membrane oxygenation, seizures, and spinal cord injury resulting in paralysis from the waist down.

<a id='d2cf7381-3546-4171-b235-c443167b9afd'></a>

- Height: 129 cm, 29th percentile, -0.57 z score
- Weight: 28 kg, 45th percentile, -0.13 z score
- Body mass index: 16.83 kg/m², 60th percentile, 0.27 z score

<a id='ab8a6eb6-b33d-4256-9ee7-c086833efeaa'></a>

*Assessed Nutrition Needs*

*   Basal metabolic rate (BMR) (Schofield): 1063 kcal (38 kcal/kg)
*   Estimated energy needs: 38–46 kcal/kg [BMR – (BMR × 1.2)] with critical illness
*   Estimated protein needs: 1.5–2 g/kg with critical illness
*   Estimated fluid needs: per team
*   Micronutrient needs: recommended dietary allowance (RDA) for age

<a id='0aeb4f75-ecbd-43b0-a024-5a26f09086d7'></a>

Trophic feeds initiated postoperative day 5 with standard non-fiber-containing
formula at 15 mL every 3 hours via gastrostomy tube. Registered nurse noted
formula coming out of orogastric tube when tube unclamped. With desire to
advance feeds more rapidly, nasojejunal (NJ) tube was placed under fluoroscopy.
Feeds resumed and advanced by 5 mL/h every 6 hours to goal of 50 mL/h for 1200
mL (43 mL/kg), 1200 kcal (43 kcal/kg), and 36 g protein (1.3 g/kg) with
consideration of adding a protein modular once at goal feeds. Patient was
monitored for signs and symptoms of refeeding syndrome. There was no change
noted in electrolytes or nutrition-related physical examination.

<a id='a5ee3c8f-a81a-4f23-8209-4604165a76f9'></a>

After 6 days on NJ feeds, patient was noted to have improved bowel sounds and motility, with decreasing gastrostomy tube output and subsequent tolerance of gastrostomy tube clamped. Feeds were transitioned from NJ to gastrostomy tube continuous feeds. Bowel regimen started with MiraLAX, Senna, daily glycerin suppositories, and as-needed enemas because of difficulty stooling. Once full feedings were tolerated via gastrostomy tube, the formula was transitioned to standard fiber-containing formula, and protein modular was added to formula to increase protein intake, with slow-healing wound requiring a wound vac. By this time, patient had undergone diuresis postoperatively and was maintaining weights 27–29 kg. Total fluid volume was still restricted, with numerous intravenous (IV)

<a id='1a992131-1215-40a9-8bff-d3a8bbf831df'></a>

medications still providing additional fluid as well as clinical status not appropriate for additional fluids.

<a id='af3fcdd5-c68c-4d74-84a9-90d100a7f1e9'></a>

Patient proceeded to have tracheostomy placed. Postoperatively, feeds were transitioned from continuous to bolus feeding via gastrostomy tube: 240 mL over 2 hours for 5 feedings per day. Over the next several days, the time feeds were given over was decreased by 30 min/d until feeds were given over 30 minutes 5 times per day. Patient passed a video fluoroscopic swallow study and was allowed to take liquids with the speech language pathologist, and she drank 60 mL of water twice daily. As IV medications were weaned, water flushes of 60 mL after each of 5 feedings were provided for a total volume of 420 mL water daily in addition to the 1200 mL of formula. Additional protein was continued until wounds were healed. Micronutrient supplementation was not needed because patient was receiving great than 1 L/d of pediatric formula, which met the RDAs for age.

<a id='109d8cd1-eec0-479f-9f4c-95e1a9c3e66e'></a>

## Infant Patient
Patient: 5-month-old female admitted with respiratory distress due to respiratory syncytial virus requiring intubation and mechanical ventilation. Physical examination reveals well-nourished-appearing infant with no nutrition-related physical findings. Parents report home intakes of 5.5–6 oz 6 times per day of standard, milk-based infant formula for approximately 33–36 oz/d of total intakes when well. Intakes have been decreased to about 20 oz/d for the past 2 days. Parents confirm they follow the instructions on the can to mix the formula to 20 cal/oz. Infant has not trialed any other foods or beverages. Parents report no micronutrient supplementation.

<a id='2845c712-3039-4244-a388-0b25c335996a'></a>

* Length: 60 cm, 5th percentile, -1.68 z score
* Weight: 6 kg, 15th percentile, -1.04 z score
* Head circumference: 40 cm, 15th percentile, -1.02 z score
* Weight for length: 59th percentile, 0.23 z score

<a id='1e385521-b410-431a-816e-7949fc03dee4'></a>

Review of the growth chart reveals age-appropriate weight gain and linear growth for age.

<a id='81cfe58c-0ce1-447c-8360-72e622678191'></a>

**Assessed Nutrition Needs**
* RDA for age: 108 kcal/kg, 2.2 g/kg protein, home intakes reported at 110–120 kcal/kg
* Estimated energy needs: 90–100 kcal/kg/d (while intubated)
* Estimated protein needs: 2.2–3 g/kg/d
* Estimated fluid needs: 100 mL/kg/d minimum

<a id='5e25d4b6-c4b3-4339-8907-a44467d65be7'></a>

Nasogastric (NG) bolus feeds begin the day of intubation with home infant formula of standard dilution at 30 mL every 4 hours and advanced by 30 mL every feeding to goal of 150 mL to provide 100 kcal/kg/d. Feeds are well tolerated.

<a id='2f2c767d-40a2-46e7-9891-9dccc4097168'></a>

Patient is extubated after 3 days and is cleared by speech language pathologist
to start taking formula via bottle with every other feed. Patient is transitioned to a by

<a id='e3197d3c-a3c2-48e2-8890-c81a46f9baf7'></a>

mouth/NG bolus schedule, and feedings are increased to home intakes of 180 mL per feeding. She is able to take 40%-50% of feedings offered by mouth and is liberalized to take a bottle at each feeding time. After 2 days, intakes are consistently greater than 85% of feeding volumes with demonstrated weight gain meeting goals for age, and NG tube is removed. No micronutrient supplementation was added because patient was meeting needs with more than 1 L of infant formula intakes.

<a id='bb78058e-efca-4c89-93f7-2701136f9474'></a>

APPENDIX 5-2. Standard Infant Formulas
<table id="2-1">
<tr><td id="2-2">Formula</td><td id="2-3">Protein Type</td><td id="2-4">Whey/Casein</td><td id="2-5">Carbohydrate Source</td><td id="2-6">Prebiotics</td></tr>
<tr><td id="2-7">Enfamil Enspire (Mead Johnson)</td><td id="2-8">Nonfat milk, whey protein concentrate</td><td id="2-9">60:40</td><td id="2-a">Lactose</td><td id="2-b">Galacto-oligosaccharides, polydextrose</td></tr>
<tr><td id="2-c">Enfamil NeuroPro Infant (Mead Johnson)</td><td id="2-d">Nonfat milk, whey protein concentrate</td><td id="2-e">60:40</td><td id="2-f">Lactose</td><td id="2-g">Galacto-oligosaccharides, polydextrose, 2'-FL</td></tr>
<tr><td id="2-h">Enfamil Simply Organic (Mead Johnson)</td><td id="2-i">Nonfat milk, whey protein concentrate</td><td id="2-j">60:40</td><td id="2-k">Organic lactose, organic maltodextrin</td><td id="2-l">Organic galacto-oligosaccharides</td></tr>
<tr><td id="2-m">Gerber Good Start GentlePro (Gerber)</td><td id="2-n">Hydrolyzed whey protein</td><td id="2-o">100% whey</td><td id="2-p">Lactose, maltodextrin</td><td id="2-q">2'-FL HMO, probiotic: Bifidobacterium lactis</td></tr>
<tr><td id="2-r">Similac 360 Total Care (Abbott Nutrition)</td><td id="2-s">Nonfat milk, whey protein concentrate</td><td id="2-t">48:52</td><td id="2-u">Lactose</td><td id="2-v">HMOs (2'-FL, lacto-N-tetraose, 3-fucosyllactose, 6'-sialyllactose, 3'-sialyllactose)</td></tr>
<tr><td id="2-w">Similac Organic (Abbott Nutrition)</td><td id="2-x">Organic nonfat milk</td><td id="2-y">18:82</td><td id="2-z">Organic lactose</td><td id="2-A">Short-chain fructo-oligosaccharides</td></tr>
</table>

<a id='5ced8ab5-79a7-436f-be76-82abfca07438'></a>

Abbreviations: 2'-FL, 2'-fucosyllactose; HMO, human milk oligosaccharide.
Note: All values accurate at the time of publication. Always check with manufacturer for the most up-to-date information.

<a id='1f8a892b-9f2b-442a-ae47-148e98ea9412'></a>

APPENDIX 5-3. Reduced-Lactose Infant Formulas
<table id="3-1">
<tr><td id="3-2">Formula</td><td id="3-3">Protein Type</td><td id="3-4">Whey/Casein</td><td id="3-5">Carbohydrate Source</td><td id="3-6">Prebiotic</td></tr>
<tr><td id="3-7">Enfamil NeuroPro Gentlease (Mead Johnson)</td><td id="3-8">Partially hydrolyzed nonfat milk and whey protein concentrate solids (soy)</td><td id="3-9">60:40</td><td id="3-a">Corn syrup solids (80% less lactose than standard formula)</td><td id="3-b">2'-Fucosyllactose</td></tr>
<tr><td id="3-c">Enfamil Reguline (Mead Johnson)</td><td id="3-d">Partially hydrolyzed nonfat milk and whey protein concentrate solids (soy)</td><td id="3-e">60:40</td><td id="3-f">Corn syrup solids, lactose (50%)</td><td id="3-g">Polydextrose, galacto-oligo-saccharides</td></tr>
<tr><td id="3-h">Gerber Good Start Soothe (Gerber)</td><td id="3-i">Partially hydrolyzed whey protein</td><td id="3-j">100% whey</td><td id="3-k">Lactose (30%), maltodextrin</td><td id="3-l">2'-Fucosyllactose, probiotic: Limosilactoba-cillus reuteri</td></tr>
<tr><td id="3-m">Similac 360 Total Care Sensitive (Abbott Nutrition)</td><td id="3-n">Milk protein isolate</td><td id="3-o">18:82</td><td id="3-p">Sugar, corn syrup</td><td id="3-q">Human milk oligosaccharides (2'-fucosyllactose, lacto-N-tetraose, 3-fucosyllactose, 6'-sialyllactose, 3'-sialyllactose)</td></tr>
<tr><td id="3-r">Similac Pro-Total Comfort (Abbott Nutrition)</td><td id="3-s">Whey protein hydrolysate</td><td id="3-t">100% whey</td><td id="3-u">Maltodextrin (corn), sugar (98% lactose free)</td><td id="3-v">2'-Fucosyllactose, short-chain fructo-oligo-saccharides</td></tr>
</table>

<a id='64f5494b-c3fb-4380-b970-f2277f421cd9'></a>

Note: All values accurate at the time of publication. Always check with manufacturer for the most up-to-date information.

<a id='088f55d9-df61-4623-8aec-8473842e0335'></a>

APPENDIX 5-4. Soy Infant Formulas
<table id="3-w">
<tr><td id="3-x">Formula</td><td id="3-y">Protein Type</td><td id="3-z">Carbohydrate Source</td></tr>
</table>

<a id='14c179e6-e80a-4917-8ea1-7d51ad5ea34d'></a>

<table id="4-1">
<tr><td id="4-2">Formula</td><td id="4-3">Protein Type</td><td id="4-4">Carbohydrate Source</td></tr>
<tr><td id="4-5">Earth's Best Non-GMO Plant Based (Earth's Best)</td><td id="4-6">Soy protein</td><td id="4-7">Corn syrup solids</td></tr>
<tr><td id="4-8">Enfamil ProSobee Simply Plant-Based (Mead Johnson)</td><td id="4-9">Soy protein isolate</td><td id="4-a">Corn syrup solids</td></tr>
<tr><td id="4-b">Gerber Good Start Gentle Soy (Gerber)</td><td id="4-c">Hydrolyzed soy protein isolate</td><td id="4-d">Maltodextrin (corn), sucrose</td></tr>
<tr><td id="4-e">Similac Soy Isomil (Abbott Nutrition)</td><td id="4-f">Soy protein isolate</td><td id="4-g">Corn syrup solids, sugar</td></tr>
</table>

<a id='63559b15-832c-4a2b-9acb-4358a1e98f4c'></a>

Abbreviation: GMO, genetically modified organism.
Note: All values accurate at the time of publication. Always check with manufacturer
for the most up-to-date information.

<a id='021bf96c-3a39-413f-afa7-53e9c619d9a2'></a>

APPENDIX 5-5. Extensively Hydrolyzed Protein Infant Formulas

<table id="4-h">
<tr><td id="4-i">Formula</td><td id="4-j">Protein Type</td><td id="4-k">Whey/Casein</td><td id="4-l">Carbohydrate Source</td><td id="4-m">MCT Percentage</td><td id="4-n">Probiotic</td></tr>
<tr><td id="4-o">Gerber Extensive HA (Gerber)</td><td id="4-p">Whey protein hydrolysate</td><td id="4-q">100% whey</td><td id="4-r">• Maltodextrin, potato starch • Contains probiotic</td><td id="4-s">49</td><td id="4-t">Bifido-bacterium lactis</td></tr>
<tr><td id="4-u">Nutramigen with Probiotic LGG (Mead Johnson)</td><td id="4-v">Casein hydrolysate</td><td id="4-w">100% casein, free amino acids</td><td id="4-x">Corn syrup solids, modified corn starch</td><td id="4-y">—</td><td id="4-z">LGG</td></tr>
<tr><td id="4-A">Pregestimil (Mead Johnson)</td><td id="4-B">Casein hydrolysate</td><td id="4-C">100% casein</td><td id="4-D">Corn syrup solids, modified corn starch</td><td id="4-E">55</td><td id="4-F">None</td></tr>
<tr><td id="4-G">Similac Alimentum (Abbott Nutrition)</td><td id="4-H">Casein hydrolysate</td><td id="4-I">100% casein, free amino acids</td><td id="4-J">• Maltodextrin (corn), sugar • Ready-to-feed is corn free</td><td id="4-K">33</td><td id="4-L">Prebiotic: 2'-fucosyl-lactose</td></tr>
</table>

<a id='630f829c-08fb-46e9-a5a2-496f6d569ede'></a>

Abbreviations: HA, hypoallergenic; LGG, *Lactobacillus rhamnosus* GG; MCT, medium-chain triglyceride.

Note: All values accurate at the time of publication. Always check with manufacturer for the most up-to-date information.

<a id='90de08ac-6f92-4bd9-ba2a-1e90ea68c007'></a>

APPENDIX 5-6. Elemental Infant Formulas
<table id="5-1">
<tr><td id="5-2">Formula</td><td id="5-3">Protein Type</td><td id="5-4">Carbohydrate Source</td><td id="5-5">MCT Percentage</td><td id="5-6">Other Information</td></tr>
<tr><td id="5-7">Alfamino Infant (Nestlé)</td><td id="5-8">Amino acids</td><td id="5-9">Corn syrup solids, potato starch</td><td id="5-a">43</td><td id="5-b">—</td></tr>
<tr><td id="5-c">EleCare Infant (Abbott Nutrition)</td><td id="5-d">Amino acids</td><td id="5-e">Corn syrup solids</td><td id="5-f">33</td><td id="5-g">—</td></tr>
<tr><td id="5-h">Neocate Infant DHA/ARA (Nutricia)</td><td id="5-i">Amino acids</td><td id="5-j">Corn syrup solids</td><td id="5-k">33</td><td id="5-l">—</td></tr>
<tr><td id="5-m">Neocate Syneo Infant (Nutricia)</td><td id="5-n">Amino acids</td><td id="5-o">Corn syrup solids</td><td id="5-p">33</td><td id="5-q">Prebiotics: fructo-oligosaccharides (oligofructose [4%], inulin [0.5%]), probiotic: Bifidobacterium breve M-16V</td></tr>
<tr><td id="5-r">PurAmino (Mead Johnson)</td><td id="5-s">Amino acids</td><td id="5-t">Corn syrup solids, modified tapioca starch</td><td id="5-u">33</td><td id="5-v">Contains soy oil</td></tr>
</table>

<a id='28c39e61-3965-44b1-a329-ffee8498b34e'></a>

Abbreviation: MCT, medium-chain triglyceride.
Note: All values accurate at the time of publication. Always check with manufacturer for the most up-to-date information.

<a id='f0633eb7-398b-4c0d-880c-7fa0199399d0'></a>

APPENDIX 5-7. Added Rice Starch Infant Formulas
<table id="5-w">
<tr><td id="5-x">Product</td><td id="5-y">Protein Type</td><td id="5-z">Whey/Casein</td><td id="5-A">Carbohydrate Source</td><td id="5-B">Prebiotic</td></tr>
<tr><td id="5-C">Enfamil A.R. (Mead Johnson)</td><td id="5-D">Nonfat milk, whey protein concentrate</td><td id="5-E">20:80</td><td id="5-F">Lactose, rice starch, maltodextrin</td><td id="5-G">Galacto-oligosaccharides, polydextrose</td></tr>
<tr><td id="5-H">Similac for Spit Up (Abbott Nutrition)</td><td id="5-I">Milk protein isolate</td><td id="5-J">18:82</td><td id="5-K">Corn syrup, rice starch, sugar</td><td id="5-L">Galacto-oligosaccharides</td></tr>
</table>

<a id='4cf84d75-a166-4ad1-819e-3b963819c06a'></a>

*Note*: All values accurate at the time of publication. Always check with manufacturer for the most up-to-date information.

<a id='9ebe946a-6f3a-41a8-bc16-0ee9db6e1e8d'></a>

APPENDIX 5-8. Other Specialized Infant Formulas

<a id='5e544431-d7ff-4218-85ed-f30222dfb042'></a>

<table id="6-1">
<tr><td id="6-2">Formula</td><td id="6-3">Protein Type</td><td id="6-4">Whey/Casein Ratio</td><td id="6-5">Carbohydrate Source</td><td id="6-6">Notes</td></tr>
<tr><td id="6-7">Enfaport (Mead Johnson)</td><td id="6-8">Nonfat milk, whey protein concentrate</td><td id="6-9">60:40</td><td id="6-a">Corn syrup solids</td><td id="6-b">83% of fat as MCT</td></tr>
<tr><td id="6-c">LIPIstartª (Vitaflo)</td><td id="6-d">Whey protein concentrate</td><td id="6-e">—</td><td id="6-f">Corn syrup</td><td id="6-g">75% of fat as MCT</td></tr>
<tr><td id="6-h">Monogenª (Nutricia)</td><td id="6-i">Skim milk powder, whey protein concentrate, caseinate</td><td id="6-j">29:61</td><td id="6-k">Maltodextrin</td><td id="6-l">84% of fat as MCT</td></tr>
<tr><td id="6-m">Similac PM 60/40 (Abbott Nutrition)</td><td id="6-n">Whey protein concentrate, sodium caseinate</td><td id="6-o">60:40</td><td id="6-p">Lactose</td><td id="6-q">• Reduced minerals; calcium to phosphorous ratio designed to manage calcium disorders • Requires iron supplementation as appropriate</td></tr>
</table>

<a id='ab877c60-d680-4112-b73a-7a76314be192'></a>

Abbreviation: MCT, medium-chain triglyceride.
Note: All values accurate at the time of publication. Always check with manufacturer
for the most up-to-date information.
a Suited for >1 year of age per manufacturer.

<a id='246f0cf9-9120-4169-9f87-5ae9ad0ed6d0'></a>

APPENDIX 5-9. Pediatric Elemental Formula
<table id="6-r">
<tr><td id="6-s">Product</td><td id="6-t">Protein Type</td><td id="6-u">Carbohydrate Source</td><td id="6-v">Percentage of Fat as MCTs</td><td id="6-w">Notes</td></tr>
<tr><td id="6-x">Alfamino Junior (Nestlé)</td><td id="6-y">Amino acids</td><td id="6-z">Corn syrup solids, potato starch</td><td id="6-A">65</td><td id="6-B">—</td></tr>
<tr><td id="6-C">EleCare Junior (Abbott Nutrition)</td><td id="6-D">Amino acids</td><td id="6-E">Corn syrup solids</td><td id="6-F">33</td><td id="6-G">Additional flavors: vanilla, chocolate, banana</td></tr>
</table>

<a id='23fbdd58-c924-4fda-b9c6-3ad242f314fb'></a>

<table id="7-1">
<tr><td id="7-2">Product</td><td id="7-3">Protein Type</td><td id="7-4">Carbohydrate Source</td><td id="7-5">Percentage of Fat as MCTs</td><td id="7-6">Notes</td></tr>
<tr><td id="7-7">Neocate Junior (Nutricia)</td><td id="7-8">Amino acids</td><td id="7-9">Corn syrup solids</td><td id="7-a">35</td><td id="7-b">Additional flavors: vanilla, chocolate, strawberry, tropical</td></tr>
<tr><td id="7-c">Neocate Junior with Prebiotics (Nutricia)</td><td id="7-d">Amino acids</td><td id="7-e">Corn syrup solids</td><td id="7-f">35</td><td id="7-g">Prebiotics: fructo-oligosaccharides, inulin</td></tr>
<tr><td id="7-h">Neocate Splash (Nutricia)</td><td id="7-i">Amino acids</td><td id="7-j">Maltodextrin, sugar</td><td id="7-k">35</td><td id="7-l">Additional flavors: orange-pineapple, grape, tropical fruit, vanilla</td></tr>
<tr><td id="7-m">PurAmino Junior (Mead Johnson)</td><td id="7-n">Amino acids</td><td id="7-o">Corn syrup solids, modified tapioca starch</td><td id="7-p">33</td><td id="7-q">Also available in vanilla</td></tr>
<tr><td id="7-r">Vivonex Pediatric (Nestlé)</td><td id="7-s">Amino acids</td><td id="7-t">Maltodextrin, modified corn starch</td><td id="7-u">70</td><td id="7-v">Standard dilution: 0.8 kcal/mL</td></tr>
</table>

<a id='4e39791f-60bf-4e07-8cff-c600ccd098c1'></a>

Abbreviation: MCT, medium-chain triglyceride.

Note: All values accurate at the time of publication. Always check with manufacturer for the most up-to-date information.

<a id='db16a49f-1edc-409e-96d5-93748fd37dcb'></a>

APPENDIX 5-10. Pediatric Semi-Elemental Formula
<table id="7-w">
<tr><td id="7-x">Product</td><td id="7-y">Protein Type</td><td id="7-z">Carbohydrate Source</td><td id="7-A">Percentage of Fat as MCTs</td><td id="7-B">Notes</td></tr>
<tr><td id="7-C">Kate Farms Pediatric Peptide 1.0 Vanilla (Kate Farms)</td><td id="7-D">Organic hydrolyzed pea protein</td><td id="7-E">Organic brown rice syrup solids, organic agave syrup, organic pea starch</td><td id="7-F">50</td><td id="7-G">8 g/L organic agave inulin</td></tr>
<tr><td id="7-H">Kate Farms Pediatric Peptide 1.5 (Kate Farms)</td><td id="7-I">Organic hydrolyzed pea protein</td><td id="7-J">Organic brown rice syrup solids, organic agave syrup, organic pea starch</td><td id="7-K">50</td><td id="7-L">Also available in vanilla</td></tr>
</table>

<a id='c720595b-620d-467a-8f9a-a21f8673c5b1'></a>

<table id="8-1">
<tr><td id="8-2">Product</td><td id="8-3">Protein Type</td><td id="8-4">Carbohydrate Source</td><td id="8-5">Percentage of Fat as MCTs</td><td id="8-6">Notes</td></tr>
<tr><td id="8-7">PediaSure Peptide (Abbott Nutrition)</td><td id="8-8">Whey protein hydrolysate, hydrolyzed sodium caseinate</td><td id="8-9">Corn maltodextrin</td><td id="8-a">60</td><td id="8-b">Additional flavors: vanilla, chocolate, strawberry</td></tr>
<tr><td id="8-c">PediaSure Peptide 1.5 Vanilla (Abbott Nutrition)</td><td id="8-d">Whey protein hydrolysate, hydrolyzed sodium caseinate</td><td id="8-e">Corn maltodextrin</td><td id="8-f">60</td><td id="8-g">3 g/L fructo-oligosaccharides</td></tr>
<tr><td id="8-h">Peptamen Jr (Nestlé)</td><td id="8-i">Hydrolyzed whey protein</td><td id="8-j">Maltodextrin, corn starch</td><td id="8-k">60</td><td id="8-l">Additional flavors: vanilla, strawberry</td></tr>
<tr><td id="8-m">Peptamen Jr High Protein (Nestlé)</td><td id="8-n">Hydrolyzed whey protein (16% of calories from protein)</td><td id="8-o">Maltodextrin, sugar, corn starch</td><td id="8-p">60</td><td id="8-q">4 g/L PHGG (soluble fiber); 1.2 kcal/mL</td></tr>
<tr><td id="8-r">Peptamen Jr PHGG (Nestlé)</td><td id="8-s">Hydrolyzed whey protein</td><td id="8-t">Maltodextrin, sugar, corn starch</td><td id="8-u">60</td><td id="8-v">12 g/L PHGG (soluble fiber) 1.2 kcal/mL</td></tr>
<tr><td id="8-w">Peptamen Jr 1.5 (Nestlé)</td><td id="8-x">Hydrolyzed whey protein</td><td id="8-y">Maltodextrin, corn starch</td><td id="8-z">60</td><td id="8-A">6 g/L PHGG (soluble fiber)</td></tr>
<tr><td id="8-B">Peptamen Jr with Fiber (Nestlé)</td><td id="8-C">Hydrolyzed whey protein</td><td id="8-D">Maltodextrin, sugar, corn starch</td><td id="8-E">60</td><td id="8-F">8 g/L pea fiber (insoluble fiber) and PHGG (soluble fiber)</td></tr>
<tr><td id="8-G">Vital Peptide 1.5 Vanilla (Abbott Nutrition)</td><td id="8-H">Whey protein hydrolysate, hydrolyzed sodium caseinate</td><td id="8-I">Corn maltodextrin, sugar</td><td id="8-J">55</td><td id="8-K">Intended for ages 14+</td></tr>
</table>

<a id='dd79233d-61d8-483b-8f1a-ed542a8df269'></a>

Abbreviation: MCT, medium-chain triglyceride.
Note: All values accurate at the time of publication. Always check with manufacturer for the most up-to-date information.

<a id='f019379d-5fbe-4afc-bcd6-26386ff9a343'></a>

APPENDIX 5-11. Pediatric Standard Formula

<a id='bffc5ba5-ea63-489b-a636-6ecdf570fcfc'></a>

<table id="9-1">
<tr><td id="9-2">Product</td><td id="9-3">Protein Type</td><td id="9-4">Carbohydrate Source</td><td id="9-5">Percentage of Fat as MCTs</td><td id="9-6">Notes</td></tr>
<tr><td id="9-7">Boost Kid Essentials 1.0 (Nestlé)</td><td id="9-8">Milk protein concentrate</td><td id="9-9">Brown rice syrup, sugar</td><td id="9-a">0</td><td id="9-b">Flavors: vanilla, chocolate, strawberry</td></tr>
<tr><td id="9-c">Boost Kid Essentials 1.5 (Nestlé)</td><td id="9-d">Milk protein concentrate</td><td id="9-e">Brown rice syrup, sugar</td><td id="9-f">10</td><td id="9-g">Flavors: vanilla, chocolate, strawberry</td></tr>
<tr><td id="9-h">Boost Kid Essentials 1.5 with Fiber (Nestlé)</td><td id="9-i">Milk protein concentrate</td><td id="9-j">Brown rice syrup, sugar</td><td id="9-k">10</td><td id="9-l">8 g/L pea fiber (insoluble fiber) and partially hydrolyzed guar gum (soluble fiber)</td></tr>
<tr><td id="9-m">Kate Farms Pediatric Standard 1.2 Vanilla (Kate Farms)</td><td id="9-n">Organic pea protein</td><td id="9-o">Organic brown rice syrup solids, organic agave syrup</td><td id="9-p">40</td><td id="9-q">12g/L organic agave inulin; also available in chocolate</td></tr>
<tr><td id="9-r">Nutren Jr (Nestlé)</td><td id="9-s">Milk protein concentrate, whey protein concentrate (50%)</td><td id="9-t">Maltodextrin, sugar</td><td id="9-u">20</td><td id="9-v">Also available in vanilla</td></tr>
<tr><td id="9-w">Nutren Jr with Fiber (Nestlé)</td><td id="9-x">Milk protein concentrate, whey protein concentrate (50%)</td><td id="9-y">Maltodextrin, sugar</td><td id="9-z">20</td><td id="9-A">6 g/L pea fiber, fructo-oligo- saccharides, inulin</td></tr>
<tr><td id="9-B">PediaSure Enteral (Abbott Nutrition)</td><td id="9-C">Milk protein concentrate, soy protein isolate</td><td id="9-D">Corn maltodextrin, sugar</td><td id="9-E">15</td><td id="9-F">—</td></tr>
<tr><td id="9-G">PediaSure Enteral with Fiber (Abbott Nutrition)</td><td id="9-H">Milk protein concentrate, soy protein isolate</td><td id="9-I">Corn maltodextrin, sugar</td><td id="9-J">15</td><td id="9-K">13 g/L oat fiber, soy fiber, fructo- oligosaccharides</td></tr>
</table>

<a id='2c9ddec7-d79c-4acf-9a9d-eb1e5ad3457c'></a>

<table id="10-1">
<tr><td id="10-2">Product</td><td id="10-3">Protein Type</td><td id="10-4">Carbohydrate Source</td><td id="10-5">Percentage of Fat as MCTs</td><td id="10-6">Notes</td></tr>
<tr><td id="10-7">PediaSure Enteral 1.5 (Abbott Nutrition)</td><td id="10-8">Milk protein concentrate, soy protein isolate</td><td id="10-9">Corn maltodextrin</td><td id="10-a">10</td><td id="10-b">—</td></tr>
<tr><td id="10-c">PediaSure Enteral 1.5 with Fiber (Abbott Nutrition)</td><td id="10-d">Milk protein concentrate, soy protein isolate</td><td id="10-e">Corn maltodextrin, sugar</td><td id="10-f">10</td><td id="10-g">13 g/L oat fiber, soy fiber fructo-oligosaccharides</td></tr>
</table>

<a id='416d661f-ab55-4942-a8b4-f9db6092dce0'></a>

Abbreviation: MCT, medium-chain triglyceride.
*Note*: All values accurate at the time of publication. Always check with manufacturer for the most up-to-date information.

<a id='26410e84-1a0b-4b4c-9f82-d8a281816257'></a>

APPENDIX 5-12. Pediatric Real Food–Based Formula
<table id="10-h">
<tr><td id="10-i">Product</td><td id="10-j">Protein Type</td><td id="10-k">Carbohydrate Source</td><td id="10-l">MCT Percentage</td><td id="10-m">Fiber</td></tr>
<tr><td id="10-n">Compleat Pediatric (Nestlé)</td><td id="10-o">Dehydrated chicken powder, milk protein concentrate, pea protein isolate</td><td id="10-p">Brown rice syrup, fruits, vegetables</td><td id="10-q">20</td><td id="10-r">8 g/L fruits, vegetables, pea fiber, fructo-oligosaccharides, inulin</td></tr>
<tr><td id="10-s">Compleat Pediatric Reduced Calorie (0.6 kcal/mL) (Nestlé)</td><td id="10-t">Dehydrated chicken powder, milk protein concentrate, pea protein isolate</td><td id="10-u">Brown rice syrup, fruits, vegetables</td><td id="10-v">20</td><td id="10-w">10 g/L fruits, vegetables, pea fiber, fructo-oligosaccharides, inulin</td></tr>
<tr><td id="10-x">Compleat Pediatric Peptide 1.5 (Nestlé)</td><td id="10-y">Hydrolyzed pea protein isolate, l-cystine</td><td id="10-z">Brown rice syrup, fruits, vegetables</td><td id="10-A">40</td><td id="10-B">12 g/L partially hydrolyzed guar gum, fruits, vegetables</td></tr>
<tr><td id="10-C">Compleat Pediatric Standard 1.0 (Nestlé)</td><td id="10-D">Pea protein isolate, l-cystine</td><td id="10-E">Brown rice syrup</td><td id="10-F">20</td><td id="10-G">10 g/L partially hydrolyzed guar gum, pea fiber</td></tr>
</table>

<a id='b58891cf-093d-4bb6-abde-38d60511d205'></a>

<table id="11-1">
<tr><td id="11-2">Product</td><td id="11-3">Protein Type</td><td id="11-4">Carbohydrate Source</td><td id="11-5">MCT Percentage</td><td id="11-6">Fiber</td></tr>
<tr><td id="11-7">Compleat Pediatric Standard Plant Based 1.4 (Nestlé)</td><td id="11-8">Pea protein isolate, l-cystine</td><td id="11-9">Brown rice syrup</td><td id="11-a">20</td><td id="11-b">10 g/L partially hydrolyzed guar gum, pea fiber</td></tr>
<tr><td id="11-c">Compleat Pediatric Organic Blends Chicken-Garden Blend (1.2 kcal/mL) (Nestlé)</td><td id="11-d">Organic chicken, organic brown rice flour, organic hydrolyzed pea protein</td><td id="11-e">Organic fruits, vegetables, organic brown rice flour</td><td id="11-f">0</td><td id="11-g">3 g/300 mL organic fruits, vegetables, organic brown rice flour, organic hydrolyzed pea protein</td></tr>
<tr><td id="11-h">Compleat Pediatric Organic Blends Plant Based Blend (1.2 kcal/mL) (Nestlé)</td><td id="11-i">Organic sweet potato, organic brown rice flour, organic hydrolyzed pea protein, organic rice protein concentrate</td><td id="11-j">Organic fruits, vegetables, organic brown rice flour</td><td id="11-k">0</td><td id="11-l">5 g/300 mL organic fruits, vegetables, organic brown rice flour, organic hydrolyzed pea protein</td></tr>
<tr><td id="11-m">Nourish (Functional Formularies)</td><td id="11-n">Organic pea protein, organic whole grain brown rice, organic garbanzo beans, organic green peas, organic sprouted quinoa</td><td id="11-o">Organic vegetables, organic garbanzo beans, organic green peas, organic whole grain brown rice, organic sprouted quinoa, organic pea protein</td><td id="11-p">0</td><td id="11-q">7 g/355 mL organic vegetables, organic garbanzo beans, organic green peas, organic whole grain brown rice, organic sprouted quinoa, organic pea protein</td></tr>
<tr><td id="11-r">PediaSure Harvest (Abbott Nutrition)</td><td id="11-s">Organic brown rice, soy protein isolate, organic rice protein concentrate</td><td id="11-t">Organic fruits, vegetables, organic brown rice</td><td id="11-u">0</td><td id="11-v">8 g/L organic fruits, vegetables, organic brown rice</td></tr>
</table>

<a id='373a853e-9f5d-401c-ab10-088a6a09eaad'></a>

<table id="12-1">
<tr><td id="12-2">Product</td><td id="12-3">Protein Type</td><td id="12-4">Carbohydrate Source</td><td id="12-5">MCT Percentage</td><td id="12-6">Fiber</td></tr>
<tr><td id="12-7">Real Food Blendsª (Real Food Blends)</td><td id="12-8">Varies: turkey, chicken, beef, egg, salmon, quinoa</td><td id="12-9">Fruits, vegetables</td><td id="12-a">—</td><td id="12-b">Varies: fruits, vegetables</td></tr>
</table>

<a id='758163c8-0f1a-42f1-875b-3940cc67b0a8'></a>

Abbreviation: MCT, medium-chain triglyceride.

Note: All values accurate at the time of publication. Always check with manufacturer for the most up-to-date information.

a Not nutritionally complete.

<a id='eac4312e-6fea-4d99-b800-db9f7548ab81'></a>

APPENDIX 5-13. Standard Adult Formulas
<table id="12-c">
<tr><td id="12-d">Product</td><td id="12-e">Protein Type</td><td id="12-f">Carbohydrate Source</td><td id="12-g">Fiber</td><td id="12-h">Notes</td></tr>
<tr><td id="12-i">Fibersource HN (Nestlé)</td><td id="12-j">Milk (casein), soy</td><td id="12-k">Glucose syrup, maltodextrin</td><td id="12-l">15.2 g/L pea fiber, fructo-oligosaccharides, inulin</td><td id="12-m">1.2 kcal/mL</td></tr>
<tr><td id="12-n">Isosource HN (Nestlé)</td><td id="12-o">Milk (casein), Soy</td><td id="12-p">Corn syrup, maltodextrin</td><td id="12-q">None</td><td id="12-r">1.2 kcal/mL</td></tr>
<tr><td id="12-s">Isosource 1.5 (Nestlé)</td><td id="12-t">Milk (casein), soy</td><td id="12-u">Glucose syrup, maltodextrin</td><td id="12-v">15.2 g/L pea fiber, fructo-oligosaccharides, inulin</td><td id="12-w">—</td></tr>
<tr><td id="12-x">Jevity 1.0 (Abbott Nutrition)</td><td id="12-y">Milk (casein), soy</td><td id="12-z">Corn maltodextrin, corn syrup solids</td><td id="12-A">14.4 g/L soy fiber</td><td id="12-B">—</td></tr>
<tr><td id="12-C">Jevity 1.2 (Abbott Nutrition)</td><td id="12-D">Milk (casein), soy</td><td id="12-E">Corn maltodextrin, corn syrup solids</td><td id="12-F">17 g/L soy and oat fiber, short-chain fructo-oligosaccharides</td><td id="12-G">—</td></tr>
<tr><td id="12-H">Jevity 1.5 (Abbott Nutrition)</td><td id="12-I">Milk (casein), Soy</td><td id="12-J">Corn maltodextrin, corn syrup solids</td><td id="12-K">21 g/L soy and oat fiber, short-chain fructo-oligosaccharides</td><td id="12-L">—</td></tr>
<tr><td id="12-M">Nutren 1.0 (Nestlé)</td><td id="12-N">Milk (casein), soy</td><td id="12-O">Corn syrup, maltodextrin</td><td id="12-P">None</td><td id="12-Q">—</td></tr>
</table>

<a id='a2c7f992-62a2-4624-85dd-c1f4b93584f5'></a>

<table id="13-1">
<tr><td id="13-2">Product</td><td id="13-3">Protein Type</td><td id="13-4">Carbohydrate Source</td><td id="13-5">Fiber</td><td id="13-6">Notes</td></tr>
<tr><td id="13-7">Nutren 1.0 Fiber (Nestlé)</td><td id="13-8">Milk (casein), soy</td><td id="13-9">Corn syrup, maltodextrin</td><td id="13-a">12 g/L pea fiber, fructo-oligo- saccharides, inulin</td><td id="13-b">—</td></tr>
<tr><td id="13-c">Nutren 1.5 (Nestlé)</td><td id="13-d">Milk (casein), soy</td><td id="13-e">Corn syrup, maltodextrin</td><td id="13-f">None</td><td id="13-g">—</td></tr>
<tr><td id="13-h">Nutren 2.0 (Nestlé)</td><td id="13-i">Milk (casein), soy</td><td id="13-j">Corn syrup, maltodextrin</td><td id="13-k">None</td><td id="13-l">—</td></tr>
<tr><td id="13-m">Osmolite 1.0 (Abbott Nutrition)</td><td id="13-n">Milk (casein), soy</td><td id="13-o">Corn maltodextrin, corn syrup solids</td><td id="13-p">None</td><td id="13-q">—</td></tr>
<tr><td id="13-r">Osmolite 1.2 (Abbott Nutrition)</td><td id="13-s">Milk (casein)</td><td id="13-t">Corn maltodextrin</td><td id="13-u">None</td><td id="13-v">—</td></tr>
<tr><td id="13-w">Osmolite 1.5 (Abbott Nutrition)</td><td id="13-x">Milk (casein), soy</td><td id="13-y">Corn maltodextrin, corn syrup solids</td><td id="13-z">None</td><td id="13-A">—</td></tr>
<tr><td id="13-B">Promote (Abbott Nutrition)</td><td id="13-C">Milk (casein), soy</td><td id="13-D">Corn maltodextrin, sugar</td><td id="13-E">None</td><td id="13-F">Available in vanilla flavor</td></tr>
<tr><td id="13-G">Promote with Fiber (Abbott Nutrition)</td><td id="13-H">Milk (casein), soy</td><td id="13-I">Corn maltodextrin, sugar</td><td id="13-J">14.4 g/L oat fiber, soy fiber</td><td id="13-K">—</td></tr>
<tr><td id="13-L">Replete (Nestlé)</td><td id="13-M">Milk (casein)</td><td id="13-N">Corn syrup, maltodextrin</td><td id="13-O">None</td><td id="13-P">—</td></tr>
<tr><td id="13-Q">Replete with Fiber (Nestlé)</td><td id="13-R">Milk (casein), soy</td><td id="13-S">Corn syrup, maltodextrin</td><td id="13-T">12 g/L pea fiber, fructo-oligosaccharides, inulin</td><td id="13-U">—</td></tr>
<tr><td id="13-V">TwoCal HN (Abbott Nutrition)</td><td id="13-W">Milk (casein)</td><td id="13-X">Corn syrup solids, corn maltodextrin, sugar</td><td id="13-Y">None</td><td id="13-Z">2 kcal/mL; available in vanilla flavor</td></tr>
</table>

<a id='f1593a78-904d-4871-a741-5552a1791b1c'></a>

Note: All values accurate at the time of publication. Always check with manufacturer for the most up-to-date information.

<a id='e8b3f36e-f972-4166-9415-0431c7a45b7e'></a>

APPENDIX 5-14. Adult Semi-Elemental Formulas
<table id="14-1">
<tr><td id="14-2">Product</td><td id="14-3">Protein Type</td><td id="14-4">Carbohydrate Source</td><td id="14-5">Fiber</td><td id="14-6">Notes</td></tr>
<tr><td id="14-7">Impact Peptide 1.5 (Nestlé)</td><td id="14-8">Hydrolyzed whey (milk)</td><td id="14-9">Maltodextrin, cornstarch</td><td id="14-a">None</td><td id="14-b">—</td></tr>
<tr><td id="14-c">Peptamen (Nestlé)</td><td id="14-d">Hydrolyzed whey (milk)</td><td id="14-e">Maltodextrin, corn starch</td><td id="14-f">None</td><td id="14-g">—</td></tr>
<tr><td id="14-h">Peptamen AF (Nestlé)</td><td id="14-i">Hydrolyzed whey (milk)</td><td id="14-j">Maltodextrin, corn starch</td><td id="14-k">6 g/L inulin, fructo-oligo-saccharides</td><td id="14-l">1.2 kcal/mL</td></tr>
<tr><td id="14-m">Peptamen with Prebio (Nestlé)</td><td id="14-n">Hydrolyzed whey (milk)</td><td id="14-o">Maltodextrin, corn starch</td><td id="14-p">12 g/L inulin, fructo-oligo-saccharides</td><td id="14-q">Available in vanilla flavor</td></tr>
<tr><td id="14-r">Peptamen 1.5 (Nestlé)</td><td id="14-s">Hydrolyzed whey (milk)</td><td id="14-t">Maltodextrin, corn starch</td><td id="14-u">None</td><td id="14-v">—</td></tr>
<tr><td id="14-w">Peptamen 1.5 with Prebio (Nestlé)</td><td id="14-x">Hydrolyzed whey (milk)</td><td id="14-y">Maltodextrin, sugar, corn starch</td><td id="14-z">6.4 g/L inulin, fructo-oligo-saccharides</td><td id="14-A">—</td></tr>
<tr><td id="14-B">Peptamen Intense VHP (Nestlé)</td><td id="14-C">Hydrolyzed whey (milk)</td><td id="14-D">Maltodextrin, corn starch</td><td id="14-E">4 g/L inulin, fructo-oligo-saccharides</td><td id="14-F">92 g/L protein</td></tr>
<tr><td id="14-G">Perative (Abbott Nutrition)</td><td id="14-H">Hydrolyzed whey and casein (milk)</td><td id="14-I">Maltodextrin (corn)</td><td id="14-J">6.4 g/L fructo-oligosaccharides</td><td id="14-K">—</td></tr>
<tr><td id="14-L">Pivot 1.5 (Abbott Nutrition)</td><td id="14-M">Hydrolyzed whey and casein (milk)</td><td id="14-N">Corn syrup solids</td><td id="14-O">7.2 g/L fructo-oligosaccharides</td><td id="14-P">—</td></tr>
<tr><td id="14-Q">Vital (Abbott Nutrition)</td><td id="14-R">Hydrolyzed whey and casein (milk)</td><td id="14-S">Corn maltodextrin, sugar</td><td id="14-T">4 g/L fructo-oligosaccharides</td><td id="14-U">Available in vanilla flavor</td></tr>
<tr><td id="14-V">Vital 1.5 (Abbott Nutrition)</td><td id="14-W">Hydrolyzed whey and casein (milk)</td><td id="14-X">Corn maltodextrin, sugar</td><td id="14-Y">5.6 g/L fructo-oligosaccharides</td><td id="14-Z">—</td></tr>
<tr><td id="14-10">Vital AF 1.2 (Abbott Nutrition)</td><td id="14-11">Hydrolyzed whey and casein (milk)</td><td id="14-12">Corn maltodextrin</td><td id="14-13">5.1 g/L fructo-oligosaccharides</td><td id="14-14">Available in vanilla flavor</td></tr>
<tr><td id="14-15">Vital High Protein (Abbott Nutrition)</td><td id="14-16">Hydrolyzed whey and casein (milk)</td><td id="14-17">Corn maltodextrin</td><td id="14-18">—</td><td id="14-19">87.3 g/L protein</td></tr>
</table>

<a id='c199618f-6ef7-4eb2-9c92-f18c65682d9d'></a>

*Note*: All values accurate at the time of publication. Always check with manufacturer for the most up-to-date information.

<a id='f7424f32-0bc5-426d-af3e-5831707b4845'></a>

APPENDIX 5-15. Other Adult Formulas
<table id="15-1">
<tr><td id="15-2">Product</td><td id="15-3">Protein Type</td><td id="15-4">Carbohydrate Source</td><td id="15-5">Fiber</td><td id="15-6">Notes</td></tr>
<tr><td id="15-7">Nepro Vanilla (Abbott Nutrition)</td><td id="15-8">Milk protein isolate, caseinates</td><td id="15-9">Corn syrup solids, sugar</td><td id="15-a">25g/L corn fiber, short-chain fructo-oligosaccharides</td><td id="15-b">Also available in mixed berry and butter pecan; 1.8 kcal/mL</td></tr>
<tr><td id="15-c">Novasource Renal Vanilla (Nestlé)</td><td id="15-d">Milk (casein), soy</td><td id="15-e">Corn syrup, sugar, maltodextrin</td><td id="15-f">None</td><td id="15-g">Also available in café mocha and strawberry; 2 kcal/mL</td></tr>
<tr><td id="15-h">Nutren Pulmonary (Nestlé)</td><td id="15-i">Milk (casein)</td><td id="15-j">Sugar, maltodextrin</td><td id="15-k">None</td><td id="15-l">1.5 kcal/mL; 100 g/L carbohydrate</td></tr>
<tr><td id="15-m">Pulmocare (Abbott Nutrition)</td><td id="15-n">Milk (casein)</td><td id="15-o">Sugar, corn maltodextrin</td><td id="15-p">None</td><td id="15-q">1.5 kcal/mL; 105.7 g/L carbohydrate</td></tr>
<tr><td id="15-r">Suplena Vanilla (Abbott Nutrition)</td><td id="15-s">Milk (casein)</td><td id="15-t">Corn maltodextrin, isomaltulose, sugar</td><td id="15-u">24 g/L corn fiber, short-chain fructo-oligosaccharides</td><td id="15-v">1.8 kcal/mL</td></tr>
<tr><td id="15-w">Tolerex (Nestlé)</td><td id="15-x">Free amino acids</td><td id="15-y">Maltodextrin, modified cornstarch</td><td id="15-z">None</td><td id="15-A">2 g fat/L Safflower oil</td></tr>
<tr><td id="15-B">Vivonex Plus (Nestlé)</td><td id="15-C">Free amino acids</td><td id="15-D">Maltodextrin, modified cornstarch</td><td id="15-E">None</td><td id="15-F">6.7 g fat/L Soybean oil</td></tr>
<tr><td id="15-G">Vivonex RTF (Nestlé)</td><td id="15-H">Free amino acids</td><td id="15-I">Maltodextrin, modified cornstarch</td><td id="15-J">None</td><td id="15-K">11.6 g fat/L Soybean oil, MCT</td></tr>
<tr><td id="15-L">Vivonex T.E.N. (Nestlé)</td><td id="15-M">Free amino acids</td><td id="15-N">Maltodextrin, modified cornstarch</td><td id="15-O">None</td><td id="15-P">2.6 g fat/L Safflower oil</td></tr>
</table>

<a id='531c714e-065c-4c8a-a3fe-28a8b041765c'></a>

Abbreviation: MCT, medium-chain triglyceride.
Note: All values accurate at the time of publication. Always check with manufacturer
for the most up-to-date information.

<a id='3d1cd8a4-b749-4ce7-b7d8-449342aaf528'></a>

APPENDIX 5-16. Product Manufacturer Websitesª
<table id="16-1">
<tr><td id="16-2">Company</td><td id="16-3">Website</td></tr>
<tr><td id="16-4">Abbott Nutrition</td><td id="16-5">https://abbottnutrition.com/</td></tr>
<tr><td id="16-6">Earth's Best</td><td id="16-7">https://www.earthsbest.com/</td></tr>
<tr><td id="16-8">Functional Formularies</td><td id="16-9">https:/www.functionalformularies.com/</td></tr>
<tr><td id="16-a">Gerber</td><td id="16-b">https://www.gerber.com/gerber-good-start</td></tr>
<tr><td id="16-c">Kate Farms</td><td id="16-d">https://www.katefarms.com/</td></tr>
<tr><td id="16-e">Mead Johnson</td><td id="16-f">https://www.meadjohnson.com/</td></tr>
<tr><td id="16-g">Nestlé</td><td id="16-h">https://www.nestlehealthscience.com/</td></tr>
<tr><td id="16-i">Nutricia</td><td id="16-j">https://nutricia-na.com/</td></tr>
<tr><td id="16-k">Real Food Blends</td><td id="16-l">https://www.realfodblends.com/</td></tr>
<tr><td id="16-m">Vitaflo</td><td id="16-n">https://www.vitafloUSA.com/</td></tr>
</table>

<a id='678455de-6e72-4c76-b3f1-4dbbf296e82a'></a>

Note: All values accurate at the time of publication. Always check manufacturer information for the most up-to-date information.
a All values accurate at time of creation. Always check with manufacturer for the most up-to-date nutrition information.

<a id='9b1f2a20-6404-475b-89ef-820c41d544b3'></a>

6

<a id='a862d47f-e4e5-4548-8cd4-207df61db182'></a>

Parenteral Nutrition

<a id='80483062-9bf6-4bec-8801-763fe2848b8d'></a>

Elaina Szeszycki, PharmD
Francine Breckler, PharmD, BCPPS

<a id='7de82349-57fe-42a7-ae40-da06e5c74a52'></a>

# Indications for Parenteral Nutrition

Parenteral nutrition (PN) is a therapeutic option for patients who are unable to tolerate an enteral diet. Prior to the initiation of PN, a complete evaluation of enteral delivery options should be considered. Consensus guidelines published by ASPEN in 2017 outlined appropriate PN use as follows¹:

* Identify clinical indicators for PN such as impaired gastrointestinal (GI) absorption, mechanical bowel obstruction, or motility disorders.
* Identify clinical scenarios in which PN may not be indicated.
* Ensure appropriate selection of vascular access devices.
* Take measures to ensure safe use of PN and decrease adverse effects.
* Ensure continual PN evaluation, including ongoing need.
* Transition to oral nutrition or enteral nutrition (EN) when feasible.
* Collaborate with multiple disciplines to ensure appropriate therapy decisions and outcomes.

<a id='70e0e004-3735-4653-8b60-8f1ad46dcc8a'></a>

The focus of this chapter is to provide a concise review of PN therapy including vascular access selection, initiation of PN, doses of macro- and micronutrients, PN monitoring, and long-term management.

<a id='6bbfa84e-09e1-457d-beff-2a94976cc047'></a>

Vascular Access for PN

<a id='3b0c182d-614c-4006-b862-b540453c5c1b'></a>

Selection of a vascular access device for PN requires careful consideration that should account for length of catheter use, patient characteristics, vascular access history, location of PN administration (hospital vs home), and family input.¹ Different peripheral and central access devices are available that carry their own risks and benefits. To assist with selection of a catheter, The Michigan Appropriateness Guide for Intravenous Catheters in Pediatrics (miniMAGIC) was developed to provide clinical guidance for selection of a vascular access device based on length of catheter use and type of intravenous (IV) solution.² The miniMAGIC guidelines are summarized in Table 6-1. Table 6-2 highlights each catheter type, access location, advantages, and disadvantages. ¹,³⁻⁵ Figure 6-1 provides a pictorial representation of a peripherally inserted central catheter (PICC) and nontunneled and tunneled central venous catheters.

<a id='37ac2405-6cd2-4782-8300-26f43e1a3d55'></a>

TABLE 6-1. Summary of miniMAGIC Guidelines
<table id="18-1">
<tr><td id="18-2">Age</td><td id="18-3">Duration of Catheter Need (Days)</td><td id="18-4">Peripherally Compatible IV Solution</td><td id="18-5">Non–Peripherally Compatible IV Solution</td></tr>
<tr><td id="18-6">Hospitalized infant ≤ 1 y</td><td id="18-7">≤ 14 d 15–30 d ≥ 31 d</td><td id="18-8">PIV PICC Tunneled CVC, PICC</td><td id="18-9">PICC, nontunneled CVC PICC PICC, tunneled CVC, implantable CVC (port)</td></tr>
<tr><td id="18-a">Hospitalized child >1 y</td><td id="18-b">≤ 14 d 15–30 d ≥ 31 d</td><td id="18-c">PIV, midline PICC PICC, tunneled CVC, implantable CVC (port)</td><td id="18-d">PICC, nontunneled CVC PICC PICC, nontunneled CVC, implantable CVC (port)</td></tr>
</table>

<a id='6706a61b-da4f-4269-9381-e62d4efd0e33'></a>

Abbreviations: CVC, central venous catheter; IV, intravenous; miniMAGIC, Michigan
Appropriateness Guide for Intravenous Catheters in Pediatrics; PICC, peripherally
inserted central catheter; PIV, peripheral IV.

<a id='42c2a5d6-d483-4194-b1be-8598146af70c'></a>

TABLE 6-2. Location, Advantages, and Disadvantages of
Vascular Access Devices
<table id="19-1">
<tr><td id="19-2">Vascular Access Device</td><td id="19-3">Location of Access</td><td id="19-4">Advantages</td><td id="19-5">Disadvantages</td></tr>
<tr><td id="19-6">Peripheral IV catheter</td><td id="19-7">Hand, antecubital, scalp veins</td><td id="19-8">Lower cost of placement Can be placed by nursing personnel Low infection risk</td><td id="19-9">Limited to solutions with osmolarity <900 mOsm/L Phlebitis Possibility of extravasation and tissue damage Not useful for home PN</td></tr>
<tr><td id="19-a">Midline catheter</td><td id="19-b">Proximal basilic or cephalic veins</td><td id="19-c">May retain in place longer than peripheral IV line Decreased rate of phlebitis</td><td id="19-d">Limited to solutions with osmolarity <900 mOsm/L Not useful for home PN</td></tr>
<tr><td id="19-e">PICC</td><td id="19-f">Basilic, brachial or cephalic vein</td><td id="19-g">Decreased risk of pneumothorax May be used for short/medium duration PN Can be used for blood draws Easily removed Lower infection risk compared with CVC</td><td id="19-h">Deep vein thrombosis Coiling and malposition Dislodgement</td></tr>
<tr><td id="19-i">Nontunneled CVC</td><td id="19-j">Internal jugular vein, subclavian vein, and femoral vein</td><td id="19-k">Can infuse hyperosmolar intravenous solutions Useful for acute care settings</td><td id="19-l">Infection Dislodgement Not useful for home PN Thrombosis</td></tr>
<tr><td id="19-m">Tunneled CVC</td><td id="19-n">Subclavian or internal jugular vein</td><td id="19-o">• Can be used long term • Useful for home PN therapy</td><td id="19-p">• Infection • Thrombosis • Occlusion</td></tr>
</table>

<a id='a0ef9b68-2667-48e5-af36-78659780522c'></a>

<table id="20-1">
<tr><td id="20-2">Vascular Access Device</td><td id="20-3">Location of Access</td><td id="20-4">Advantages</td><td id="20-5">Disadvantages</td></tr>
<tr><td id="20-6">Implantable CVC (port)</td><td id="20-7">Subclavian or internal jugular vein</td><td id="20-8">• Longest duration of access • Lowest risk for infection • No local care needed if not accessed</td><td id="20-9">• Requires surgical removal • Limited use for PN administration because of need for frequent accessing</td></tr>
</table>

<a id='e8417bf8-290d-4ff0-82b6-c101564065b8'></a>

Abbreviations: CVC, central venous catheter; IV, intravenous; PICC, peripherally inserted central catheter; PN, parenteral nutrition.

<a id='f452898b-1a49-4d73-9e25-0ea504c3c95e'></a>

<::The image displays three diagrams illustrating different types of central venous catheters in a child's torso, each with labels indicating insertion points and catheter paths.

**PICC Line**
A diagram showing a catheter inserted into the arm at the elbow. The catheter tubing runs up the arm and into the chest, with its tip located in a large vein near the heart. Key labels include: "PICC Line", "Incision to insert catheter" (pointing to the insertion site on the upper arm), "Elbow" (pointing to the bend of the arm), "Tip of catheter tubing in large vein near heart" (pointing to the catheter's end in the chest), and "Access port" (pointing to the external connection on the catheter).

**Temporary Central Line**
A diagram showing a catheter inserted into the neck/upper chest area. The catheter tubing enters the body and its tip is in a large vein near the heart. Key labels include: "Temporary Central Line", "Incision to insert catheter" (pointing to the insertion site on the neck/upper chest), "Access port" (pointing to the external connection), and "Tip of catheter tubing in large vein near heart" (pointing to the catheter's end in the chest).

**Tunneled Catheter**
A diagram showing a catheter inserted into the neck, with the tubing tunneled under the skin before exiting the body on the chest. The tip of the catheter is in a large vein near the heart. Key labels include: "Tunneled Catheter", "Incision to insert catheter" (pointing to the insertion site on the neck), "Catheter tubing under skin" (indicating the path of the tubing beneath the skin), "Exit site" (pointing to where the catheter emerges from the skin on the chest), "Access port" (pointing to the external connection), and "Tip of catheter tubing in large vein near heart" (pointing to the catheter's end in the chest).
: figure::>

<a id='af86ffa7-793d-4030-9ea2-ca701c96bf11'></a>

FIGURE 6-1. Access types and locations of select central venous access devices in children. PICC, peripherally inserted central catheter. Reproduced with permission from the Children's Hospital of Philadelphia. Copyright 2014 by the Children's Hospital of Philadelphia.

<a id='3e7065be-12be-4936-8f89-17a70977bccc'></a>

## PN Ordering and Safety Considerations

PN is a complex IV solution that requires specialized expertise to ensure that the order is both safe and effective. Although PN can improve

<a id='490e728e-70ff-434b-a0a4-ddec6425f37d'></a>

nutrition status, EN is still preferred over PN because of decreased complications and cost. The indication for PN must be carefully considered to determine appropriateness as use can expose patients to unnecessary procedures, potential harm, and increased costs. Assessment, prescription, and review are 3 important steps in the PN ordering process.

<a id='ae16cf86-a531-40e6-81aa-589fde26d2de'></a>

1. Assessment
* Evaluation of patient history
* Physical and caloric requirements
* Access options
2. Prescription
* Indication for PN
* Patient weight
* Macronutrients ordered as g/kg/d or g/d
* Order based on access (peripheral or central)
* Desired PN volume
* Nutrition goals for macronutrients
* Choice of electrolytes including decision for selection of cations and anions as determined by the patient's acid/base status ordered as mEq/kg/d or mEq/d
* Micronutrients (use of a commercially available trace metal package vs prescribing each individually)
* Multivitamins
* Additives (Carnitine, heparin, etc)
3. Review
* Appropriate route of administration
* Appropriate weight
* Current date and time
* Correct PN prescription form for weight and age
* Infusion rate within usual limits for weight and age (mL/kg/d or mL/h)
* Macronutrients, micronutrient, medication additives within usual dosing limits
* Multivitamin ordered based on weight and age
* Trace minerals ordered based on weight and age
* Appropriate ordering units (grams, milligrams, micrograms, millimoles, etc)
* Calcium and phosphorus solubility within limits
* Formulation within all stability limits
* Osmolarity not exceeded if peripheral PN ordered

<a id='222458be-de64-4bdd-b322-d496bdb29ea1'></a>

All disciplines should be involved in assessing, prescribing, ordering, administering, evaluating, and monitoring PN prescriptions daily. A multidisciplinary team review process creates an environment that allows each discipline to use their expertise to provide excellent patient care and outcomes.7

<a id='a2f714b4-a436-49af-ad3c-1d724b1bd94d'></a>

## Access Considerations
The type of access will determine whether a peripheral or central PN can be ordered. Central access is preferred for PN administration, especially for those patients who will require long-term IV nutrition. The use of peripheral nutrition is limited by the osmolarity of the solution that in turn limits the calorie content of the PN. Exhibit 6-1 lists the considerations for use of peripheral PN when this is the only access available.8

<a id='bafefcf9-2813-437b-9d72-62c9d7424693'></a>

EXHIBIT 6-1. Considerations for Peripheral Parenteral Nutrition

* Limited by osmolarity (60–900 mOsm/L [institution specific])
* Generally, will not meet 100% of estimated calories and protein
* Used for short-term nutrition support (3–7 d) until transitioned to CPN or EN
* Maximum dextrose concentration 12.5%
* Osmolarity driven by amino acids, dextrose, sodium, potassium, and calcium
* Monitor closely for phlebitis or infiltration of intravenous line

Abbreviations: CPN, central parenteral nutrition; EN, enteral nutrition.

<a id='1bec3b6f-e8e8-46ae-8cf8-0dcc473c96bc'></a>

**Use of 2-in-1 vs 3-in-1 PN**

The PN can be ordered as amino acid/dextrose solution with the lipids co-infused (2-in-1) or all 3 macronutrients added to one bag (3-in-1). These types of PN can be customized for the needs of the individual patient. Commercially available premade solutions can be considered in select situations as an option, especially in times of product shortages.9
Advantages of the 3-in-1 PN includes compounding efficiency, less contamination risk during administration, and potential cost savings.8
Disadvantages of the 3-in-1 include potential for emulsion destabilization and medication incompatibility with the solution.8 When considering a 2-in-1 vs 3-in-1 formulation, the choice of formulation type may be dictated by the amount of access available for nutrition (number of lumens), current stability, compatibility information for PN, lipid formulation, and patient medications.10

<a id='f11f6a49-6d63-4442-a9e1-1892de3bec4a'></a>

# Use of Filters and Photoprotection

## Filters

Filters are available in a variety of sizes and are essential for trapping particulate matter, microbes, air, and large lipid droplets. Particulate matter can include rubber, silicone, fibers, and drug/mineral precipitates. Highlights of ASPEN's best practices for use of filters with PN include the following¹¹:

*   Ensure pharmacist review of the stability and compatibility of the PN solution.
*   Perform a visual inspection of the PN.
*   If a 2-in-1 PN solution is ordered, the amino acids and dextrose should be set up first, and the infusion pump should be programmed before setting up the lipid infusion.
*   Avoid co-administration of medications if possible.
*   Ensure use of appropriate flushing techniques before and after medication administration.
*   If a medication must be co-administered with the PN, the medication tubing should be attached at a Y-site above the filter.
*   Medications that cannot be filtered should not be given with PN.
*   Use a 1.2-µm filter for all PN admixtures.

<a id='16501485-78f6-4dc8-b1f1-4b590dc6bbbb'></a>

# Photoprotection

Components of the PN including lipid injectable emulsions (ILEs) can undergo oxidation when exposed to light, which leads to production of free radicals. 12 Infants, especially those born prematurely, are at highest risk. Photoprotection recommendations from ASPEN include both the bag and infusion sets. ASPEN also recommends complete PN light protection starting during the compounding of the PN and continuing until the bag is completely infused. Complete implementation of these recommendations may not be feasible, but individual health care organizations should bring together experts to discuss how these recommendations could be achieved. 12

<a id='010f7b23-5083-456e-9487-8e31a0a90207'></a>

*Calculating PN Fluid Requirements*

The PN fluid volume is usually based on the patient's maintenance
requirements. Other clinical factors can impact how much fluid the
patient will require. For example, the volume may need to be increased

<a id='a13ad671-056f-45ce-a955-3a4638cbf7d0'></a>

for patients who have an increased amount of ostomy output or diarrhea. A volume less than maintenance fluid may be ordered for those patients with decreased renal, liver, or cardiac function. The Holliday-Segar method is frequently used to estimate maintenance fluid requirements in pediatric patients (see chapter 4, "Infant to Adolescent," Table 4-5).13

<a id='52d6fe1a-5015-40ad-800d-985f0a34a3ab'></a>

Individualized patient assessment, especially in the critically ill child, is necessary to determine if fluid needs are above or below maintenance fluid requirements because of changes in energy expenditure and electrolyte requirements.14

<a id='87252e5f-de90-4d1d-8288-467fbc330d64'></a>

# Macronutrient Requirements

## General

The amounts of amino acids, dextrose, and ILEs are based on individual requirements. Table 6-3 provides guidance on starting dose, advancements, and general requirements for each macronutrient. 15 It may take up to 2-3 days to reach goal calories and protein based on the patient's estimated nutrition requirements. The duration of time to goal may be even longer if a patient presents moderately to severely malnourished because these patients would require a slower increase to avoid refeeding.

<a id='27a6ce70-c317-468a-9857-a03794b053bc'></a>

TABLE 6-3. Dosing for Initiation and Advancement of PN Macronutrients



<a id='17e63728-1e23-488c-81c7-c8d1c1894313'></a>

<table id="25-1">
<tr><td id="25-2"></td><td id="25-3">Initiation</td><td id="25-4">Advance By</td><td id="25-5">Goal</td></tr>
<tr><td id="25-6" colspan="4">Children (1–10 y)</td></tr>
<tr><td id="25-7">Protein (g/kg/d)</td><td id="25-8">1.5–2.5</td><td id="25-9">—</td><td id="25-a">1.5–2.5</td></tr>
<tr><td id="25-b">Dextrose (mg/kg/min)</td><td id="25-c">3–6</td><td id="25-d">1–2</td><td id="25-e">8–10</td></tr>
<tr><td id="25-f">SO-ILE</td><td id="25-g">1–2</td><td id="25-h">0.5–1</td><td id="25-i">2–2.5</td></tr>
<tr><td id="25-j" colspan="4">Adolescents</td></tr>
<tr><td id="25-k">Protein (g/kg/d)</td><td id="25-l">0.8–2</td><td id="25-m">—</td><td id="25-n">0.8–2</td></tr>
<tr><td id="25-o">Dextrose (mg/kg/min)</td><td id="25-p">2.5–3</td><td id="25-q">1–2</td><td id="25-r">5–6</td></tr>
<tr><td id="25-s">SO-ILE</td><td id="25-t">1</td><td id="25-u">1</td><td id="25-v">1–2</td></tr>
</table>

<a id='83c38c1d-4f18-4099-afd8-71a8c273ec17'></a>

Abbreviations: GIR, glucose infusion rate; PN, parenteral nutrition; SO-ILE, soybean oil-based lipid injectable emulsion.
a Adapted with permission from the American Society for Parenteral and Enteral Nutrition from ASPEN Recommendations on Appropriate Parenteral Nutrition Dosing for Neonatal and Pediatric and Neonatal Patients. 2019. Updated November 17, 2020. https://www.nutritioncare.org/uploadedFiles/Documents/Guidelines_and_Clinical_Resources/PN%20Dosing%201-Sheet-Nov%202020-FINAL.pdf
b GIR calculation in mg/kg/min = [dextrose (g/day) × 1000] / [24 (h/day) × 60 (min/h) × weight (kg)]

<a id='fdff6919-18c1-442d-bd0d-1452988692c1'></a>

Macronutrients are generally ordered in weight-based units such as g/kg/d, but in pediatric patients weighing greater than 40 kg, it may be acceptable to order them as g/d to avoid overfeeding. Initial goals for calorie needs and protein requirements are listed in chapter 4, “Infant to Adolescent,” Tables 4-1 and 4-2 These goals may need to be modified based on routine nutrition assessment by a multidisciplinary team. 16

<a id='da56588b-e3f0-4413-93d6-d2cc9efddc5a'></a>

## Amino Acids
Pediatric amino acid products are usually reserved for neonatal patients based on the original research but may still be used in younger pediatric patients and those with intestinal failure-associated liver disease (IFALD).¹⁷ The pediatric amino acid product decreases the risk of abnormal plasma amino acid levels due to reduced metabolism by

<a id='8e36f71f-0e96-4823-8a08-8e31794eb56b'></a>

immature and damaged livers. Standard amino acids are routinely used in
the remainder of our pediatric patients similarly to adult patients. Amino
acids provide energy of 4 kcal/g. Table 6-4 lists the differences in
essential and nonessential amino acids between 2 currently available
amino acid products. 18,19

<a id='28de13e8-a876-4582-8772-0aab2b68e721'></a>

TABLE 6-4. Amino Acid Variations Between Pediatric Amino
Acids and Adult or Standard Amino Acids
<table id="26-1">
<tr><td id="26-2">Amino Acid Type</td><td id="26-3">Pediatric Amino Acid</td><td id="26-4">Standard Amino Acid</td></tr>
<tr><td id="26-5" colspan="3">Essential amino acids</td></tr>
<tr><td id="26-6">Leucine (branched chain)</td><td id="26-7">Higher</td><td id="26-8">Lower</td></tr>
<tr><td id="26-9">Isoleucine (branched chain)</td><td id="26-a">Higher</td><td id="26-b">Lower</td></tr>
<tr><td id="26-c">Valine (branched chain)</td><td id="26-d">Slightly higher</td><td id="26-e">Slightly lower</td></tr>
<tr><td id="26-f">Lysine</td><td id="26-g">Similar</td><td id="26-h">Similar</td></tr>
<tr><td id="26-i">Histidine</td><td id="26-j">Slightly lower</td><td id="26-k">Slightly higher</td></tr>
<tr><td id="26-l">Phenylalanine (aromatic)</td><td id="26-m">Slightly lower</td><td id="26-n">Slightly higher</td></tr>
<tr><td id="26-o">Threonine</td><td id="26-p">Similar</td><td id="26-q">Similar</td></tr>
<tr><td id="26-r">Methionine (sulfur containing)</td><td id="26-s">Lower</td><td id="26-t">Higher</td></tr>
<tr><td id="26-u">Tyrosine (aromatic)</td><td id="26-v">Higher</td><td id="26-w">Lower</td></tr>
<tr><td id="26-x">Tryptophan (aromatic)</td><td id="26-y">Slightly higher</td><td id="26-z">Slightly lower</td></tr>
<tr><td id="26-A">Cysteine (sulfur containing)</td><td id="26-B">Small amount</td><td id="26-C">None</td></tr>
<tr><td id="26-D" colspan="3">Nonsessential amino acids</td></tr>
<tr><td id="26-E">Arginine</td><td id="26-F">Higher</td><td id="26-G">Lower</td></tr>
<tr><td id="26-H">Proline</td><td id="26-I">Slightly higher</td><td id="26-J">Slightly lower</td></tr>
<tr><td id="26-K">Alanine</td><td id="26-L">Lower</td><td id="26-M">Higher</td></tr>
<tr><td id="26-N">Glutamic acid</td><td id="26-O">Similar</td><td id="26-P">Similar</td></tr>
<tr><td id="26-Q">Serine</td><td id="26-R">Similar</td><td id="26-S">Similar</td></tr>
<tr><td id="26-T">Glycine</td><td id="26-U">Lower</td><td id="26-V">Higher</td></tr>
<tr><td id="26-W">Aspartic acid</td><td id="26-X">Slightly higher</td><td id="26-Y">Slightly lower</td></tr>
<tr><td id="26-Z">Taurine (sulfur containing)</td><td id="26-10">Small amount</td><td id="26-11">None</td></tr>
</table>

<a id='43318b95-a87a-4714-aff6-88eadef5b4fc'></a>

Dextrose

<a id='da783756-40df-435d-a70b-0abd02c88330'></a>

Carbohydrate calories are ordered as dextrose, which provides energy or 3.4 kcal/g. It is preferred to order dextrose using glucose infusion rate (GIR; mg/kg/min) in neonates and young pediatric patients or g/d in older pediatric patients. Use of percent final concentration should be avoided to prevent concentration errors and provide appropriate carbohydrate intake.20 The dextrose is advanced daily until the goal is reached as long as adequate blood glucose levels are maintained. Blood glucose levels should be monitored by daily serum or capillary glucose. Dextrose usually constitutes 60%–70% of nonprotein calories while lipid constitutes 30%–40% of nonprotein calories. The ratio or dose may vary based on blood glucose levels, triglyceride levels, carbon dioxide retention as a byproduct of carbohydrate metabolism, or development of IFALD.21,22

<a id='8704f603-7132-4226-90c6-a470d5c925bf'></a>

# Lipid Injectable Emulsions

Lipid injectable emulsions (ILEs) provide a concentrated source of calories and essential fatty acids that are required for pediatric growth and development.23 ILEs provide 10 kcal/g of energy. The first ILEs consisted of soybean oil, which contains a high concentration of omega-6 fatty acids, and phytosterols, which are thought to contribute to the development of IFALD. The availability of newer lipid emulsions has allowed clinicians to customize therapy based on individual patient needs. The choice of an ILE product should consider oil source, anticipated duration of PN use, and patient comorbidities.23 Use of soybean oil-based ILE (SO-ILE) should be limited to patients receiving short-term PN. Use of multi-oil ILEs (soy, medium-chain triglyceride [MCT], olive, fish oil-based ILE [SO,MCT,OO,FO-ILE]) should be considered for use in patients that require PN for a prolonged period of time. A fish oil-based ILE (FO-ILE) is indicated in patients who have established IFALD.23 Neonatal use of lipid emulsions will be discussed in chapter 7, “Neonatal Nutrition." Table 6-5 is a compilation of the available lipid emulsions and US Food and Drug Administration-approved indications. Table 6-6 provides the composition of the various

<a id='bd944b43-0373-4ecd-9c72-bc873563b7ec'></a>

lipid emulsions. Table 6-7 provides dosing recommendations for the ILE products.

<a id='6d4d3353-adf6-473d-8f85-5f2c0b23f90f'></a>

TABLE 6-5. Lipid Injectable Emulsion Products,
Characteristics, Abbreviations, and Approval for Use in the
United States

<a id='5b1ed4ba-cdc4-4df7-8329-8398e148ced2'></a>

<table id="29-1">
<tr><td id="29-2">Lipid Injectable Emulsion</td><td id="29-3">Characteristic</td><td id="29-4">Abbreviation</td><td id="29-5">FDA-Approved Neonatal and Pediatric Indication</td></tr>
<tr><td id="29-6"></td><td id="29-7">Lipid injectable emulsion</td><td id="29-8">ILE</td><td id="29-9"></td></tr>
<tr><td id="29-a">Intralipid (Baxter Healthcare Corporation)</td><td id="29-b">Soybean oil–based ILE</td><td id="29-c">SO-ILE</td><td id="29-d">A source of calories and EFAs for patients requiring PN for extended periods of time (usually for >5 d) and as a source of EFAs for prevention of EFAD syndromea</td></tr>
<tr><td id="29-e">Nutrilipid (B. Braun Medical, Inc)</td><td id="29-f">Soybean oil–based ILE</td><td id="29-g">SO-ILE</td><td id="29-h">A source of calories and EFAs for PN and a source of FAs when a deficiency occurs for which oral nutrition or EN is not possible, insufficient, or contraindicatedb</td></tr>
<tr><td id="29-i">SMOFlipid (Fresenius Kabi)</td><td id="29-j">Soybean, MCTs, olive, fish oil–based ILE</td><td id="29-k">SO,MCT, OO,FO-ILE, multi-oil</td><td id="29-l">A source of calories and EFAs for PN when oral or EN is not possible, insufficient, or contraindicatedc</td></tr>
<tr><td id="29-m">Omegaven (Fresenius Kabi)</td><td id="29-n">Fish oil–based ILE</td><td id="29-o">FO-ILE</td><td id="29-p">A source of calories and FAs in pediatric patients with PN-associated cholestasisd</td></tr>
<tr><td id="29-q">Clinolipid (Baxter Healthcare Corporation)</td><td id="29-r">Olive, soybean oil–based ILE</td><td id="29-s">OO,SO-ILE, Multi-oil</td><td id="29-t">FDA approval not yet attainede</td></tr>
</table>

<a id='c7178e4d-44cf-401e-b9aa-e20ca555e90f'></a>

Abbreviations: EFA, essential fatty acid; EFAD, EFA deficiency; EN, enteral nutrition; FA, fatty acid; FDA, US Food and Drug Administration; MCT, medium-chain triglyceride; PN, parenteral nutrition.

Adapted with permission from the American Society for Parenteral and Enteral Nutrition from Cober MP, Gura KM, Mirtallo JM, et al; ASPEN Parenteral Nutrition Safety Committee. ASPEN lipid injectable emulsion safety recommendations part 2: neonate and pediatric considerations. _Nutr Clin Pract_. 2021;36(6):1106–1125.

https://doi.org/10.1002/ncp.10778

a Intralipid 20%. Package insert. Fresenius Kabi; 2016.
b Nutrilipid. Package insert. B. Braun Medical Inc; 2020.
c SMOFlipid. Package insert. Fresenius Kabi; 2022.

<a id='5e1002b3-fd10-4a9f-b61a-46d5bcc0631c'></a>

d Omegaven. Package insert. Fresenius Kabi; 2018.
e Clinolipid. Package insert. Baxter Healthcare Corporation, 2016.

<a id='68155417-2091-4aa2-8f00-9410c846d5b0'></a>

TABLE 6-6. Composition and Properties of ILE Products
<table id="31-1">
<tr><td id="31-2">Category</td><td id="31-3">Componentª</td><td id="31-4">OO,SO-ILEb</td><td id="31-5">SO-ILEc</td><td id="31-6">SO-ILEd</td><td id="31-7">FO-ILEᵉ</td><td id="31-8">SO,MCT,OO,FO-ILEᶠ</td></tr>
<tr><td id="31-9" rowspan="4">Source oil</td><td id="31-a">SO, %</td><td id="31-b">20</td><td id="31-c">100</td><td id="31-d">100</td><td id="31-e">0</td><td id="31-f">30</td></tr>
<tr><td id="31-g">FO, %</td><td id="31-h">0</td><td id="31-i">0</td><td id="31-j">0</td><td id="31-k">100</td><td id="31-l">15</td></tr>
<tr><td id="31-m">MCT, %</td><td id="31-n">0</td><td id="31-o">0</td><td id="31-p">0</td><td id="31-q">0</td><td id="31-r">30</td></tr>
<tr><td id="31-s">OO, %</td><td id="31-t">80</td><td id="31-u">0</td><td id="31-v">0</td><td id="31-w">0</td><td id="31-x">25</td></tr>
<tr><td id="31-y" rowspan="4">Additives</td><td id="31-z">Egg phospholipid, g/100 mL</td><td id="31-A">1.2</td><td id="31-B">1.2</td><td id="31-C">1.2</td><td id="31-D">1.2</td><td id="31-E">1.2</td></tr>
<tr><td id="31-F">Glycerin, g/100 mL</td><td id="31-G">2.25</td><td id="31-H">2.25</td><td id="31-I">2.5</td><td id="31-J">2.5</td><td id="31-K">2.5</td></tr>
<tr><td id="31-L">a-Tocopherol, mg/100 mL</td><td id="31-M">3.2</td><td id="31-N">0</td><td id="31-O">0</td><td id="31-P">15–30</td><td id="31-Q">16.3–22.5</td></tr>
<tr><td id="31-R">Sodium oleate, g/100 mL</td><td id="31-S">0.03</td><td id="31-T">0</td><td id="31-U">0.03</td><td id="31-V">0.03</td><td id="31-W">0.03</td></tr>
<tr><td id="31-X" rowspan="3">ω-3</td><td id="31-Y">Linolenic acid, %</td><td id="31-Z">0.5–4.2</td><td id="31-10">4–11</td><td id="31-11">4–11</td><td id="31-12">1.1 (mean)</td><td id="31-13">1.5–3.5</td></tr>
<tr><td id="31-14">EPA, %</td><td id="31-15">0</td><td id="31-16">0</td><td id="31-17">0</td><td id="31-18">13–26</td><td id="31-19">1–3.5</td></tr>
<tr><td id="31-1a">DHA, %</td><td id="31-1b">0</td><td id="31-1c">0</td><td id="31-1d">0</td><td id="31-1e">14–27</td><td id="31-1f">1–3.5</td></tr>
<tr><td id="31-1g" rowspan="2">ω-6</td><td id="31-1h">Linoleic acid, %</td><td id="31-1i">13.8–22</td><td id="31-1j">44–62</td><td id="31-1k">48–58</td><td id="31-1l">1.5 (mean)</td><td id="31-1m">14–25</td></tr>
<tr><td id="31-1n">Arachidonic acid, %</td><td id="31-1o">0</td><td id="31-1p">0</td><td id="31-1q">0</td><td id="31-1r">0.2–2</td><td id="31-1s">NR</td></tr>
<tr><td id="31-1t">ω-7</td><td id="31-1u">Palmitoleic acid, %</td><td id="31-1v">0</td><td id="31-1w">0</td><td id="31-1x">0</td><td id="31-1y">4–10</td><td id="31-1z">NR</td></tr>
<tr><td id="31-1A">ω-9</td><td id="31-1B">Oleic acid, %</td><td id="31-1C">44.3–79.5</td><td id="31-1D">19–30</td><td id="31-1E">17–30</td><td id="31-1F">4–11</td><td id="31-1G">23–35</td></tr>
<tr><td id="31-1H" rowspan="6">Saturated fatty acids</td><td id="31-1I">Caprylic acid, %</td><td id="31-1J">0</td><td id="31-1K">0</td><td id="31-1L">0</td><td id="31-1M">0</td><td id="31-1N">13–24</td></tr>
<tr><td id="31-1O">Capric acid, %</td><td id="31-1P">0</td><td id="31-1Q">0</td><td id="31-1R">0</td><td id="31-1S">0</td><td id="31-1T">5–15</td></tr>
<tr><td id="31-1U">Palmitic acid, %</td><td id="31-1V">7.6–19.3</td><td id="31-1W">7–14</td><td id="31-1X">9–13</td><td id="31-1Y">4–12</td><td id="31-1Z">7–12</td></tr>
<tr><td id="31-20">Stearic acid, %</td><td id="31-21">0.7–5</td><td id="31-22">1.4–5.5</td><td id="31-23">2.5–5</td><td id="31-24">0</td><td id="31-25">1.5–4</td></tr>
<tr><td id="31-26">Myristic acid, %</td><td id="31-27">0</td><td id="31-28">0</td><td id="31-29">0</td><td id="31-2a">2-7</td><td id="31-2b">NR</td></tr>
<tr><td id="31-2c">ω-6/ω-3 ratio</td><td id="31-2d">9:1</td><td id="31-2e">7:1</td><td id="31-2f">7:1</td><td id="31-2g">1:8</td><td id="31-2h">2.5:1</td></tr>
</table>

<a id='1ce5e359-5b30-4f1d-a256-a58294edc7ba'></a>

<table id="32-1">
<tr><td id="32-2">Category</td><td id="32-3">Componentª</td><td id="32-4">OO,SO-ILEᵇ</td><td id="32-5">SO-ILEᶜ</td><td id="32-6">SO-ILEᵈ</td><td id="32-7">FO-ILEᵉ</td><td id="32-8">SO,MCT,OO,FO-ILEᶠ</td></tr>
<tr><td id="32-9"></td><td id="32-a">Phytosterols, mg/Lᵍ</td><td id="32-b">208.8 ± 39.4</td><td id="32-c">422.4 ± 130.5</td><td id="32-d">NR</td><td id="32-e">0</td><td id="32-f">142.2 ± 15.3</td></tr>
<tr><td id="32-g">Energy, kcal/mL</td><td id="32-h">—</td><td id="32-i">2</td><td id="32-j">2ʰ</td><td id="32-k">2</td><td id="32-l">1.12</td><td id="32-m">2</td></tr>
</table>

<a id='70e0519e-1a89-4984-947d-01fd9df5f311'></a>

Abbreviations: DHA, docosahexaenoic acid; EPA, eicosapentaenoic acid; FO, fish oil;
FO-ILE, FO-based ILE; ILE, lipid injectable emulsion; MCT, medium-chain triglyceride;
NR, not reported; OO, olive oil; OO,SO-ILE, OO and SO–based ILE; SO, soy oil; SO-
ILE, SO–based ILE; SO,MCT,OO,FO-ILE, SO, MCT, OO, and FO–based ILE.
Reproduced with permission from the American Society for Parenteral and Enteral
Nutrition from Cober MP, Gura KM, Mirtallo JM, et al; ASPEN Parenteral Nutrition
Safety Committee. ASPEN lipid injectable emulsion safety recommendations part 2:
neonate and pediatric considerations. Nutr Clin Pract. 2021;36(6):1106–1125.
https://doi.org/10.1002/ncp.10778

a The “%” symbol in this column refers to the percent of total oil content of the product.
b Clinolipid. Package insert. Baxter Healthcare Corporation, 2016.
c Intralipid 20%. Package insert. Fresenius Kabi; 2016.
d Nutrilipid. Package insert. B. Braun Medical Inc; 2020.
e Omegaven. Package insert. Fresenius Kabi; 2018.
f SMOFlipid. Package insert. Fresenius Kabi; 2015.
g Llop Talaverón JM, Novak A, Suñé Negre JM, Badia Tahull M, Leiva Badosa E, Ticó
Grau JR. Phytosterol determination in lipid emulsions for parenteral nutrition. Farm
Hosp. 2018;4(3):116–119. https://doi.org/10.7399/fh.10954
h This applies for the 20% product, whereas there is also a 30% product to be used for
compounding purposes only, having an energy content of 3 kcal/mL.

<a id='611ed43d-45d2-49f0-80a8-3ff94c845000'></a>

TABLE 6-7. Published Pediatric Dosage for ILE Products
<table id="33-1">
<tr><td id="33-2"></td><td id="33-3">OO,SO-ILE (g/kg/d)a,b</td><td id="33-4">SO-ILE (g/kg/d)c,d</td><td id="33-5">FO-ILE (g/kg/d)e</td><td id="33-6">SO,MCT,OO, FO-ILE (g/kg/d)f</td></tr>
<tr><td id="33-7">Preterm neonate</td><td id="33-8">3g</td><td id="33-9">3</td><td id="33-a">1g</td><td id="33-b">3g</td></tr>
<tr><td id="33-c">Term neonate, infant (0–12 mo)</td><td id="33-d">3g</td><td id="33-e">2.5–3</td><td id="33-f">1g</td><td id="33-g">3g</td></tr>
<tr><td id="33-h">Pediatric (1–10 y)</td><td id="33-i">3g</td><td id="33-j">2.5</td><td id="33-k">1g</td><td id="33-l">2.5–3g</td></tr>
<tr><td id="33-m">Adolescent (11–17 y)</td><td id="33-n">2.5g</td><td id="33-o">2–2.5</td><td id="33-p">1g</td><td id="33-q">2–2.5g</td></tr>
</table>

<a id='3b5a187a-c7e3-4282-a441-437f0a879969'></a>

Abbreviations: FO-ILE, fish oil-based ILE; ILE, lipid injectable emulsion; OO,SO-ILE, olive oil and soy oil-based ILE; SO-ILE, soy oil-based ILE; SO,MCT,OO,FO-ILE, soy oil, medium-chain triglyceride, olive oil, and fish oil-based ILE.
Reproduced with permission from the American Society for Parenteral and Enteral Nutrition from Cober MP, Gura KM, Mirtallo JM, et al; ASPEN Parenteral Nutrition Safety Committee. ASPEN lipid injectable emulsion safety recommendations part 2: neonate and pediatric considerations. Nutr Clin Pract. 2021;36(6):1106-1125.
https://doi.org/10.1002/ncp.10778
a Kerner JA Jr, Poole RL. The use of IV fat in neonates. Nutr Clin Prac. 2006;21(4):374-380.

<a id='a0da623e-48a0-4bf2-a4ab-03cb9e6a97b1'></a>

b Gura KM, Calkins KL, Puder M. Use of fish oil lipid intravenous emulsions as
monotherapy in the pediatric intestinal failure patient: beyond the package insert. *Nutr*
*Clin Pract*. 2020;35(1):108–118. https://doi.org/10.1002/ncp.10413
c Intralipid 20%. Package insert. Fresenius Kabi; 2016.
d Nutrilipid. Package insert. B. Braun Medical Inc; 2020.
e Omegaven. Package insert. Fresenius Kabi; 2018.
f Diamond IR, Grant RC, Pencharz PB, et al. Preventing the progression of intestinal
failure–associated liver disease in infants using a composite lipid emulsion: a pilot
randomized controlled trial of SMOFlipid. *JPEN J Parenter Enter Nutr*.
2017;41(5):866–877. https://doi.org/10.1177/0148607115626921
g 1.5 g/kg/d has been used off label for FO51 doses for OO, SO-ILE, and
SO, MCT,OO, FO-ILEs are also considered to be off label.

<a id='8e7a6439-8741-4e16-a23c-98ed4b0cde0b'></a>

The maximum lipid infusion rate is not clearly established for pediatric patients, but there are studies to suggest an increased risk of hypertriglyceridemia when the infusion rate exceeds 0.15 mg/kg/h.23 It is recommended to not exceed this infusion rate and reevaluate the rate with each dose change or when cycling the PN to ensure that the infusion rate remains near or below the adult maximum.

<a id='435b7f52-08f9-4756-b7ac-f67f9abe486d'></a>

**Micronutrients: Electrolytes**

Electrolytes play a large role in many physiologic functions and are added to PN solutions to maintain appropriate concentrations when the patient is unable to meet their needs enterally. The function of electrolytes is elaborated next24,25.

<a id='7c31f648-5dc8-4864-875e-eb3e30dc4139'></a>

- Sodium is the main cation in the extracellular fluid and is responsible for maintaining intravascular and interstitial fluid volumes and also supports growth and weight gain⁴⁸.
- Potassium is the major intracellular cation and is responsible for neuromuscular function and protein/glycogen synthesis.
- Chloride and acetate are the 2 main anions that are responsible for acid/base balance and osmotic pressure. Typically, the dose of sodium in the PN is matched to the dose of chloride with the rest added as acetate. These 2 anions can be manipulated in the PN as acid/base status changes. One needs to be cautious when using only chloride or acetate in the PN as this could cause large shifts in acid-base balance.
- Calcium and phosphorus are very important for bone mineralization and growth.⁸ In addition, phosphorus is an important component of adenosine triphosphate. The optimal ratio for neonatal bone mineralization is a calcium to phosphorus ratio of 1.7:1 (mg/mg) or 1.3:1 (mmol/mmol).⁷ Both calcium and phosphorus are important for the maintenance of electric impulses.
- Magnesium is important for coenzyme activation and calcium and potassium homeostasis.

<a id='66d5be1a-ed14-4cbb-8797-4698e424702b'></a>

Abnormal fluid losses as the result of diarrhea, vomiting, high nasogastric tube, or ostomy output can impact serum electrolytes. Table 6-8 provides the estimated electrolyte concentrations for different GI body fluids, which may be helpful in determining electrolyte replacement dosing. 24,26 Medications can also impact serum electrolytes. 25 Any changes to the patient's medication regimen needs to be evaluated for any potential impact on electrolyte dosing. Table 6-9 provides some of the medication classes that can impact serum electrolytes.

<a id='3e54054f-bc5f-41e2-8698-56ace442f51f'></a>

TABLE 6-8. Electrolyte Composition of Body Fluids
<table id="35-1">
<tr><td id="35-2">Fluid Type</td><td id="35-3">Sodium (mEq/L)</td><td id="35-4">Potassium (mEq/L)</td><td id="35-5">Bicarbonate (mEq/L)</td><td id="35-6">Chloride (mEq/L)</td><td id="35-7">Volume (mL/24 h)</td></tr>
<tr><td id="35-8">Gastric</td><td id="35-9">20–80</td><td id="35-a">5–20</td><td id="35-b">0</td><td id="35-c">8–154</td><td id="35-d">100–4000</td></tr>
<tr><td id="35-e">Small intestine</td><td id="35-f">100–140</td><td id="35-g">5–15</td><td id="35-h">40</td><td id="35-i">80</td><td id="35-j">100–2000</td></tr>
<tr><td id="35-k">Diarrheal stool</td><td id="35-l">10–90</td><td id="35-m">10–80</td><td id="35-n">40</td><td id="35-o">—</td><td id="35-p">—</td></tr>
<tr><td id="35-q">Ileostomy</td><td id="35-r">45–135</td><td id="35-s">3–15</td><td id="35-t">40</td><td id="35-u">43–137</td><td id="35-v">100–9000</td></tr>
<tr><td id="35-w">Colon</td><td id="35-x">60</td><td id="35-y">30</td><td id="35-z">0</td><td id="35-A">40</td><td id="35-B">—</td></tr>
<tr><td id="35-C">Bile</td><td id="35-D">131-164</td><td id="35-E">3-12</td><td id="35-F">35</td><td id="35-G">100</td><td id="35-H">50–800</td></tr>
<tr><td id="35-I">Pancreas</td><td id="35-J">113-185</td><td id="35-K">3-7</td><td id="35-L">115</td><td id="35-M">54-95</td><td id="35-N">100–800</td></tr>
</table>

<a id='97ba073f-fa5f-433a-adf5-57505d8e146f'></a>

TABLE 6-9. Drug-Induced Metabolic Disorders
<table id="35-O">
<tr><td id="35-P">Medication</td><td id="35-Q">Metabolic Disorder</td></tr>
<tr><td id="35-R">Loop diuretics</td><td id="35-S">Hyponatremia, hypokalemia, hypocalcemia, metabolic alkalosis</td></tr>
<tr><td id="35-T">Histamine 2 receptor antagonists</td><td id="35-U">Hyponatremia</td></tr>
<tr><td id="35-V">Corticosteroids</td><td id="35-W">Hypokalemia, hypocalcemia, hypophosphatemia, metabolic alkalosis</td></tr>
<tr><td id="35-X">Amphotericin B</td><td id="35-Y">Hypokalemia, hypomagnesemia, metabolic acidosis</td></tr>
<tr><td id="35-Z">Calcineurin inhibitors</td><td id="35-10">Hypomagnesemia, hyperkalemia, hypertriglyceridemia</td></tr>
<tr><td id="35-11">Aminoglycosides</td><td id="35-12">Metabolic acidosis</td></tr>
<tr><td id="35-13">Citrate</td><td id="35-14">Hypocalcemia</td></tr>
</table>

<a id='b008e18a-fd3f-4f5c-bf41-c703bbc9be4a'></a>

Monitoring of drug interactions with PN electrolytes and adjustment is an important role of the pharmacist. Electrolyte dosing for pediatric patients is based on weight and should not exceed adult starting doses (Table 6-10). Metabolic monitoring will constitute the most frequent monitoring (Table 6-11), especially early on in PN therapy, so that tolerance can be established. Electrolyte monitoring should occur daily

<a id='e890ce24-5fb3-4fc0-98a5-7e52babf57e6'></a>

for new PN starts. Once the patient is on a stable formulation, weekly or twice weekly electrolyte monitoring is possible.27

<a id='f3d5351d-514c-44e2-bbc3-32d7286b897d'></a>

TABLE 6-10. Daily Dose of Individual Electrolytes
<table id="36-1">
<tr><td id="36-2">Electrolyte</td><td id="36-3">Pediatric Dosing</td><td id="36-4">Adolescents/Children Weighing >50 kg</td></tr>
<tr><td id="36-5">Sodium</td><td id="36-6">2–5 mEq/kg</td><td id="36-7">1–2 mEq/kg</td></tr>
<tr><td id="36-8">Potassium</td><td id="36-9">2–4 mEq/kg</td><td id="36-a">1–2 mEq/kg</td></tr>
<tr><td id="36-b">Chloride and acetate</td><td id="36-c">As needed to maintain acid/base balance</td><td id="36-d">As needed to maintain acid/base balance</td></tr>
<tr><td id="36-e">Calcium</td><td id="36-f">0.5–4 mEq/kg</td><td id="36-g">10–20 mEq</td></tr>
<tr><td id="36-h">Phosphorus</td><td id="36-i">0.5–2 mmol/kg</td><td id="36-j">10–40 mmol</td></tr>
<tr><td id="36-k">Magnesium</td><td id="36-l">0.3–0.5 mEq/kg/d</td><td id="36-m">10–30 mEq/d</td></tr>
</table>

<a id='2f4200b5-e612-4711-b32b-cb81f3ffa4d5'></a>

TABLE 6-11. Frequency of Short-Term and Long-Term
Metabolic Monitoring
<table id="37-1">
<tr><td id="37-2">Parameter</td><td id="37-3">Initial</td><td id="37-4">Follow-Up</td></tr>
<tr><td id="37-5">BMP</td><td id="37-6">Daily</td><td id="37-7">Included in CMP</td></tr>
<tr><td id="37-8">Magnesium</td><td id="37-9">Daily to weekly</td><td id="37-a">Every 1–4 wk</td></tr>
<tr><td id="37-b">Phosphorus</td><td id="37-c">Daily to weekly</td><td id="37-d">Every 1–4 wk</td></tr>
<tr><td id="37-e">CMP</td><td id="37-f">Weekly</td><td id="37-g">Every 1–4 wk</td></tr>
<tr><td id="37-h">CBC with differential/platelets</td><td id="37-i">Weekly</td><td id="37-j">Every 1–4 wk</td></tr>
<tr><td id="37-k">Triglycerides</td><td id="37-l">Baseline and then weekly or as indicated</td><td id="37-m">Monthly</td></tr>
<tr><td id="37-n">GGTP</td><td id="37-o">Baseline if indicated</td><td id="37-p">Monthly</td></tr>
<tr><td id="37-q">Direct or conjugated bilirubin</td><td id="37-r">Baseline if indicated</td><td id="37-s">Every 1–4 wk</td></tr>
<tr><td id="37-t">PT/INR</td><td id="37-u">Baseline</td><td id="37-v">Monthly</td></tr>
</table>

<a id='71a75e6f-5cc7-4cf2-89bf-488f42ce77cf'></a>

Abbreviations: BMP, basic metabolic panel; CBC, complete blood cell count; CMP,
comprehensive metabolic panel; GGTP, γ-glutamyl transpeptidase; INR, international
normalized ratio; PT, prothrombin time.
Adapted with permission from the American Society for Parenteral and Enteral
Nutrition from Szeszycki E, Cruse W, McLaughlin C. Evaluation and monitoring of
pediatric patients receiving specialized nutrition support. In: Corkins MR, ed. Bobo E,
Christensen ML, Larson-Nath C, Nuse Tome R, Plogsted S, associate eds. *ASPEN
Pediatric Nutrition Support Core Curriculum*. 3rd ed. American Society for Parenteral
and Enteral Nutrition. Forthcoming 2024.

<a id='f43558c3-908a-4fee-adc4-d7ec5d272078'></a>

### Micronutrients: Multivitamins

IV multivitamins provide the fat-soluble vitamins A, D, E, and K; water-soluble B vitamins; and ascorbic acid. Multivitamins are a routine addition to daily PN solutions. A dose of 2 mL/kg/d (maximum 5 mL) is used for pediatric patients up to 11 years of age. An adult multivitamin dose of 10 mL is used for patients greater than 11 years. Table 6-12 provides a comparison of both pediatric and adult multivitamin IV products currently available.28

<a id='751cd494-9c09-4e7c-9e1a-c51cab6347e4'></a>

TABLE 6-12. Comparison of Pediatric and Adult Multivitamin
Products
<table id="38-1">
<tr><td id="38-2">Vitamin</td><td id="38-3">Infuvite: Neonatal/Pediatric, 5 mL</td><td id="38-4">Infuvite: 10 mL</td></tr>
<tr><td id="38-5">Ascorbic acid</td><td id="38-6">80 mg</td><td id="38-7">200 mg</td></tr>
<tr><td id="38-8">Vitamin A</td><td id="38-9">2300 IU</td><td id="38-a">3300 IU</td></tr>
<tr><td id="38-b">Vitamin D</td><td id="38-c">400 IU</td><td id="38-d">200 IU</td></tr>
<tr><td id="38-e">Thiamine</td><td id="38-f">1.2 mg</td><td id="38-g">6 mg</td></tr>
<tr><td id="38-h">Riboflavin</td><td id="38-i">1.4 mg</td><td id="38-j">3.6 mg</td></tr>
<tr><td id="38-k">Pyridoxine</td><td id="38-l">1 mg</td><td id="38-m">6 mg</td></tr>
<tr><td id="38-n">Niacinamide</td><td id="38-o">17 mg</td><td id="38-p">40 mg</td></tr>
<tr><td id="38-q">Dexpanthenol</td><td id="38-r">5 mg</td><td id="38-s">15 mg</td></tr>
<tr><td id="38-t">Vitamin E</td><td id="38-u">7 IU</td><td id="38-v">10 IU</td></tr>
<tr><td id="38-w">Biotin</td><td id="38-x">20 mcg</td><td id="38-y">60 mcg</td></tr>
<tr><td id="38-z">Folic acid</td><td id="38-A">140 mcg</td><td id="38-B">600 mcg</td></tr>
<tr><td id="38-C">Cyanocobalamin</td><td id="38-D">1 mcg</td><td id="38-E">5 mcg</td></tr>
<tr><td id="38-F">Vitamin K</td><td id="38-G">200 mcg</td><td id="38-H">150 mcg</td></tr>
</table>
Note: All values accurate at the time of publication.

<a id='28a7bfc2-2fe2-442c-98b7-391f6c80be1d'></a>

### Micronutrients: Trace Metals

Trace metals represent a very small component of normal dietary intake.²⁹ These micronutrients play an essential role in a variety of physiologic processes such as immune support, bone growth, and wound healing. Deficiencies of trace metals can occur when intake is inadequate or abnormal losses (GI tract) are present, which lead to adverse effects (see Table 6-13).²⁷,³⁰ If acute deficiencies are suspected, trace metal levels should be obtained. See "Long-Term PN Management" section in this chapter for recommendations on monitoring trace metals for patients on long-term PN. Trace metals can be provided in the PN solution as either individual components or as a trace metal package. Trace metals should be provided within a few days on PN initiation.³¹ Table 6-14 lists the ingredients for the currently available trace metal packages in the United States.³²,³³ The package insert lists the dose in mL/kg/d or mL/d

<a id='5210c345-c7b0-4927-873a-4d877207043f'></a>

based on weight, or institutions may develop a standardized protocol for ease of ordering. Manganese and chromium are contaminants of other IV products used to compound PN, so the need to supplement may not be required. In patients who are on long-term PN or neonates who are at risk for accumulation of these minerals, the use of the individual trace element products may be more appropriate for some patients. Individualized dosing will also allow for higher doses based on serum levels or increased need in certain populations. 34 Dosing of the individual trace metals can be found in Table 6-15.15 A sample case with subsequent PN recommendations is outlined in Appendix 6-1.

<a id='2656df1c-a583-4821-8552-67baadae2b6a'></a>

TABLE 6-13. Function of Trace Metals and Symptoms of
Deficiency
<table id="40-1">
<tr><td id="40-2">Trace Metal</td><td id="40-3">Role</td><td id="40-4">Signs of Deficiency</td></tr>
<tr><td id="40-5">Zinc</td><td id="40-6">• Growth Immune health Tissue repair</td><td id="40-7">• Dermatitis Alopecia Growth failure Alopecia</td></tr>
<tr><td id="40-8">Copper</td><td id="40-9">• Hemoglobin synthesis Bone formation Neurotransmitter synthesis</td><td id="40-a">• Neutropenia Leukopenia Hypochromic, microcytic anemia Loss of hair and skin pigmentation</td></tr>
<tr><td id="40-b">Selenium</td><td id="40-c">• Protection against oxidative stress Thyroid metabolism Immune health</td><td id="40-d">• Cardiomyopathy Myalgias Myositis Brittle hair and nails</td></tr>
<tr><td id="40-e">Chromium</td><td id="40-f">• Glucose metabolism Coenzyme</td><td id="40-g">• Hyperglycemia Weight loss Increased free fatty acids</td></tr>
<tr><td id="40-h">Manganese</td><td id="40-i">Cofactor for enzymatic reactions including those involved in immune health, reproductive health, neuronal function</td><td id="40-j">Not well documented</td></tr>
</table>

<a id='a7ba82d7-02ae-4b49-9caa-bd6491a96c76'></a>

TABLE 6-14. Ingredients for Currently Available Trace
Element Products in the United Statesª
<table id="41-1">
<tr><td id="41-2">Per 1 mL</td><td id="41-3">Tralement (Trace Element Injection 4)</td><td id="41-4">Multrys (Trace Element Injection 4 Peds)</td></tr>
<tr><td id="41-5">Zinc</td><td id="41-6">3 mg</td><td id="41-7">1 mg</td></tr>
<tr><td id="41-8">Copper</td><td id="41-9">0.3 mg</td><td id="41-a">0.06 mg</td></tr>
<tr><td id="41-b">Selenium</td><td id="41-c">60 µg</td><td id="41-d">6 µg</td></tr>
<tr><td id="41-e">Chromium</td><td id="41-f">—</td><td id="41-g">—</td></tr>
<tr><td id="41-h">Manganese</td><td id="41-i">55 µg</td><td id="41-j">3 µg</td></tr>
</table>
ª Accurate at the time of publication.

<a id='1c6d244d-c22c-4451-be54-9e97c81d9dd5'></a>

TABLE 6-15. Dosing of Trace Metals
<table id="41-k">
<tr><td id="41-l">Trace Metal</td><td id="41-m">Term Neonates/Infants, 3–10 kg (mcg/kg/d)</td><td id="41-n">Children, 10–40 kg (mcg/kg/d)</td><td id="41-o">Adolescents >40 kg (per Day)</td></tr>
<tr><td id="41-p">Zinc</td><td id="41-q">50–250</td><td id="41-r">50–125 (max 5000 mcg/d)</td><td id="41-s">2–5 mg</td></tr>
<tr><td id="41-t">Copper</td><td id="41-u">20</td><td id="41-v">20 (max 500 mcg/d)</td><td id="41-w">200–500 mcg</td></tr>
<tr><td id="41-x">Selenium</td><td id="41-y">2</td><td id="41-z">2 mcg/kg (max 100 mcg/d)</td><td id="41-A">40–60 mcg</td></tr>
<tr><td id="41-B">Chromium</td><td id="41-C">0.2</td><td id="41-D">0.2 mcg/kg (max 5 mcg/d)</td><td id="41-E">5–15 mcg</td></tr>
<tr><td id="41-F">Manganese</td><td id="41-G">1</td><td id="41-H">1 mcg/kg (max 55 mcg/d)</td><td id="41-I">40–100 mcg</td></tr>
</table>
Abbreviation: max, maximum.

<a id='90a1dd6e-0404-48d4-87ee-3369b95955b4'></a>

_**Other Micronutrients and Additives: Heparin, Carnitine, and Iron**_

Medication additives may be added to a PN solution based on patient need and compatibility with other PN ingredients. Heparin can be added at lower concentrations (0.5–1 U/mL) to central neonatal and pediatric PN solutions to aid in maintaining patency. Central venous line patency

<a id='64400b7c-650c-47f5-9622-769524c48f29'></a>

issues are common in neonatal and pediatric patients because of the small inner lumens of pediatric central line catheters, low infusion rates, and frequent infusion interruptions or co-infusion of medications based on compatibility information. 35,36

<a id='5e110391-f32f-45be-a639-8c35767dd578'></a>

Carnitine is a quaternary ammonium compound that is synthesized from lysine and methionine and is responsible for the transport of fatty acids into the mitochondria. It is present in a general diet but not in PN unless added separately. It is considered an essential nutrient in patients with renal disease on a dialysis modality, liver disease, preterm infants, metabolic disorders resulting in carnitine deficiency, and patients dependent on PN. The dose ranges from 5 to 20 mg/kg/d depending on the indication and can be monitored periodically to ensure that the dose does not need to be adjusted. 37,38

<a id='bdc56c2b-0d77-49eb-b464-16afc48ac068'></a>

Patients dependent on PN routinely develop iron deficiency anemia (IDA) because of inadequate enteral intake, inability to absorb enough iron, blood loss related to mucosal inflammation or iatrogenic blood draws, and no iron in the injectable multivitamin. Once IDA is diagnosed, based on the severity, parenteral iron may be a reasonable solution to improve iron stores and subsequent anemia status. IV iron, although effective, can be associated with a variety of side effects from nausea to anaphylaxis. Allergies and comorbidities such as asthma and prior infusion history should be evaluated before ordering IV iron. Administering IV iron in a health care setting is ideal so that appropriate monitoring and necessary supportive care can be performed. If the patient has received multiple infusions without incident, infusions of IV iron in the home may be considered with close monitoring by home nursing. Product selection is dependent on the age, weight, total dose required, convenience for the patient and family, insurance coverage, and prior infusion history. 39,40 See Table 6-16 for comparison of frequently used IV products.41

<a id='7834374f-f65b-4499-a9c5-5e5838030c92'></a>

TABLE 6-16. Composition of Frequently Used IV Iron Products

<a id='f0eaca3c-c77c-4f10-a860-6afc20e7958c'></a>

<table id="43-1">
<tr><td id="43-2">Parameter</td><td id="43-3">Ferric Carboxymaltose (Injectafer)</td><td id="43-4">Sodium Ferric Gluconate (Ferrlecit)</td><td id="43-5">Iron Sucrose (Venofer)</td><td id="43-6">Iron Dextran (INFED)</td></tr>
<tr><td id="43-7">FDA Indications</td><td id="43-8">Iron deficiency anemia, with intolerance or inadequate response to oral iron, or in non-dialysis-dependent CKD</td><td id="43-9">Hemodialysis: iron deficiency anemia, during epoetin therapy</td><td id="43-a">CKD: iron deficiency anemia</td><td id="43-b">• Iron deficiency anemia • Iron deficiency due to blood loss</td></tr>
<tr><td id="43-c">PN compatibility</td><td id="43-d">No</td><td id="43-e">No</td><td id="43-f">No</td><td id="43-g">2 in 1 only</td></tr>
<tr><td id="43-h">Total dose infusion possible</td><td id="43-i">No</td><td id="43-j">No</td><td id="43-k">No</td><td id="43-l">Yes</td></tr>
<tr><td id="43-m">Test dose</td><td id="43-n">None</td><td id="43-o">Not required</td><td id="43-p">Not required</td><td id="43-q">• Required prior to first therapeutic dose • Wait at least 1 h before giving remainder of dose • Infants <10 kg: 10 mg • Children 10–20 kg: 15 mg • Children >20 kg and adolescents: 25 mg</td></tr>
</table>

<a id='a6e4dd0c-6250-4668-b224-35a52beff739'></a>

<table id="44-1">
<tr><td id="44-2">Parameter</td><td id="44-3">Ferric Carboxymaltose (Injectafer)</td><td id="44-4">Sodium Ferric Gluconate (Ferrlecit)</td><td id="44-5">Iron Sucrose (Venofer)</td><td id="44-6">Iron Dextran (INFED)</td></tr>
<tr><td id="44-7">Pediatric dose</td><td id="44-8">Total replacement dose: Weight <50 kg: 15 mg/kg/dose (max dose: 750 mg) Weight ≥ 50 kg: 750 mg</td><td id="44-9">Total replacement dose: Children ≥ 6 y and adolescents: IV: 1.5 mg/kg of elemental iron (max: 125 mg/dose) per dialysis session</td><td id="44-a">Total replacement dose (mg of iron) = 0.6 x weight (kg) x (100 - (actual Hb/12 × 100)) First dose: For patients ≤ 14 kg: iron sucrose: up to 7 mg/kg (max: 50 mg) For patients >14 kg and <40 kg: iron sucrose: 7 mg/kg (max: 100 mg) For patients ≥ 40 kg: iron sucrose: 7 mg/kg (max: 200 mg) Subsequent doses: iron sucrose: 7 mg/kg (max: 300 mg)</td><td id="44-b">Use with caution in the first 4 mo of life Total replacement dose (mg of iron) = 0.6 x weight (kg) × (100 - (actual Hb/12) x 100)) Given as a total dose infusion or multiple doses using daily max dose up to total replacement dose</td></tr>
</table>

<a id='a5fb1ad6-6658-4746-bc7e-809baac801e1'></a>

<table id="45-1">
<tr><td id="45-2">Parameter</td><td id="45-3">Ferric Carboxymaltose (Injectafer)</td><td id="45-4">Sodium Ferric Gluconate (Ferrlecit)</td><td id="45-5">Iron Sucrose (Venofer)</td><td id="45-6">Iron Dextran (INFED)</td></tr>
<tr><td id="45-7"></td><td id="45-8">Maintenance dose: NA</td><td id="45-9">Maintenance dose: Children ≥ 6 y and adolescents <17 y: initial: 1 mg/kg/dose once weekly during dialysis session Adjust dose to desired iron indices (reported range: 0.75–1.5 mg/kg/dose) Max dose: 125 mg/dose</td><td id="45-a">Maintenance dose: IV: 5–7 mg/kg/dose every 1–7 d until total replacement dose achieved Max dose: 300 mg/dose</td><td id="45-b">Maintenance dose: Infants <5 kg: 25 mg max Children 5–10 kg: 50 mg max Children >10 kg and adolescents: 100 mg max Frequency varies depending on laboratory results</td></tr>
<tr><td id="45-c">Black box warning</td><td id="45-d">None</td><td id="45-e">None</td><td id="45-f">None</td><td id="45-g">Anaphylaxis</td></tr>
<tr><td id="45-h">Adverse events</td><td id="45-i">See package insert</td><td id="45-j">See package insert</td><td id="45-k">See package insert</td><td id="45-l">See package insert</td></tr>
</table>
Abbreviations: CKD, chronic kidney disease; FDA, US Food and Drug Administration;
Hb, hemoglobin; IV, intravenous; max, maximum; NA, not applicable.

<a id='befe6bc4-89f6-46b1-8a2a-dc3518c60aca'></a>

**Medication Compatibility With PN**

Compatibility questions are a frequent occurrence with PN to pediatric patients because of limited vascular access and volume concerns. Although infusing PN with or without lipids in a dedicated lumen is ideal as an infection prevention strategy, it may be impossible. It may be necessary to determine what medications and fluids can be added to PN or co-infused with PN. If there is no information available, or there is an incompatibility present, the nurse, pharmacist, and physician will need to

<a id='4b6ff178-c4d6-42d1-9fd4-e0a099225257'></a>

discuss alternatives, which may include more access, brief PN pause,
change to enteral, change to compatible fluid, and so forth. Exhibit 6-2
lists a variety of considerations when reviewing medication and fluid
compatibility with PN.42

<a id='a154de2e-b578-42d2-a773-72ed9470012e'></a>

EXHIBIT 6-2. Considerations When Reviewing Medication Compatibility With PN

* Medication concentration tested as a Y-site, additive, or in a syringe
* Diluent of medication
* Concentration of amino acid and dextrose in PN
* Total nutrient admixture (3-in-1 or 2-in-1)
* Electrolyte, mineral, vitamin, trace mineral additives, and medications (ie, heparin) in PN
* Organic or inorganic salts in PN
* Type, pH, inactive ingredients, salts, in amino acid product
* Type, pH, globule size in lipid product
* Temperature of testing conditions
* Duration of testing conditions
* Container used for testing

Abbreviation: PN, parenteral nutrition.

<a id='32956523-adf8-4e47-8e58-283089afbd33'></a>

_**Drug and Enteral Formula Shortages**_

Awareness of drug and enteral formula shortages are a part of the medical and nutrition support team's responsibility to ensure that appropriate alternatives are prescribed and increased monitoring is ordered as needed to identify deficiencies or toxicities early on in the shortage period. All PN ingredients have been affected at one time or another so communication among pharmacists, dietitians, nurses, care managers, home infusion providers, and medical providers is critical to avoid shortage related complications. The ASPEN website (www.nutritioncare.org) contains useful information regarding what ingredients are short and how they might be managed.43

<a id='583db480-f41e-4e7a-939f-e6c0388e5d16'></a>

**Assessing Tolerance to PN**

<a id='43af8028-0c27-49fd-8efb-91204421c8bf'></a>

Once the PN is at goal, constant monitoring and evaluation of PN adequacy begins. Exhibit 6-3 lists the parameters used to accomplish this evaluation. The rate at which these parameters change will vary based on age but should still be increasing over time because of the expectation of growth in children. Mid-upper arm circumference (MUAC), wound healing, and functional capacity are helpful measures when weight is not useful as in our patients with critical illness, liver disease, renal disease, or cardiac failure. Assessment of weight change may be difficult to interpret based on a patient's clinical status or disease process, but it is still of utmost importance to determine the etiology of weight variance and if PN volume requires adjustment. Table 6-17 lists signs and symptoms that may assist in this evaluation.

<a id='841781e9-f14b-40b0-b8d3-8706f16cde18'></a>

EXHIBIT 6-3. Parameters to Evaluate Adequacy of PN Order

* Weight
* Length or height
* Head circumference
* Weight gain
* Linear/occipital frontal circumference gain
* MUAC
* Skin or wound healing
* Functional capacity (energy and strength)

Abbreviations: MUAC, mid-upper arm circumference; PN, parenteral nutrition.

<a id='de4d9d66-bede-415a-a53e-804a0b7257eb'></a>

TABLE 6-17. Parameters to Evaluate Adequacy of PN Volume
<table id="48-1">
<tr><td id="48-2">Parameter</td><td id="48-3">Dehydration</td><td id="48-4">Fluid Overload</td></tr>
<tr><td id="48-5">Weight change; real vs fluid</td><td id="48-6">Rapid ↓ weight</td><td id="48-7">Rapid ↑ weight</td></tr>
<tr><td id="48-8">All recorded intake</td><td id="48-9">Total intake < total output</td><td id="48-a">Total intake > total output</td></tr>
<tr><td id="48-b">All recorded output</td><td id="48-c">Decreased urine output; dark urine</td><td id="48-d">Increased urine output in patients with normal renal and liver function; edema</td></tr>
<tr><td id="48-e">Laboratory</td><td id="48-f">↑ Serum urea nitrogen, ↑ sodium, ↑ serum osmolality, ↑ urine specific gravity, ↑ albumin or Hb</td><td id="48-g">↓ Sodium, serum osmolality, ↓ urine specific gravity, ↓ albumin or Hb</td></tr>
<tr><td id="48-h">Vitals</td><td id="48-i">↑ Heart rate, ↑ insensible losses with fever</td><td id="48-j">↑ Respiratory rate</td></tr>
<tr><td id="48-k">Medications</td><td id="48-l">Addition of diuretic or change in frequency</td><td id="48-m">Fluid retention with steroids or excessive sodium intake</td></tr>
<tr><td id="48-n">Physical assessment</td><td id="48-o">Thirst, dry lips, dry mucous membranes, dry skin, headaches, dizziness</td><td id="48-p">Peripheral, facial, and orbital edema, ↑ abdominal girth, shortness of breath</td></tr>
</table>

<a id='1f1f2477-9ce3-493c-8b89-9e578f336c57'></a>

Abbreviations: Hb, hemoglobin; PN, parenteral nutrition.
Adapted with permission from the American Society for Parenteral and Enteral
Nutrition from Szeszycki E, Cruse W, McLaughlin C. Evaluation and monitoring of
pediatric patients receiving specialized nutrition support. In: Corkins MR, ed. Bobo E,
Christensen ML, Larson-Nath C, Nuse Tome R, Plogsted S, associate eds. *ASPEN*
*Pediatric Nutrition Support Core Curriculum*. 3rd ed. American Society for Parenteral
and Enteral Nutrition. Forthcoming 2024.

<a id='24a1f98d-bf20-4dd9-8dd9-086137303eab'></a>

As macronutrients are advanced, monitoring for hyperglycemia,
hypertriglyceridemia, and azotemia will determine if advancement to
goal can continue or if modification is required. Electrolyte and mineral
laboratory monitoring along with evaluation of intake and outputs (see
Tables 6-11, 6-17, and 6-18) will guide the need for adjustments. Once
electrolytes and calories are stable, the frequency of metabolic
monitoring can be reduced. Baseline liver and coagulation numbers are
useful to determine if there is any cholestasis, hepatic inflammation, or

<a id='3cf3d75e-3392-4e34-8fca-97379a152e81'></a>

vitamin K deficiency present prior to initiation of PN and any need for consistent monitoring of these parameters early in PN therapy.

<a id='22f07bdc-a49a-4b7d-adff-0097c425fdac'></a>

**Refeeding Syndrome**

Refeeding syndrome (RS) occurs in patients who have had prolonged undernutrition, especially with continued electrolyte losses.44 Patients who may be at increased risk of RS include those with anorexia nervosa, malabsorption, failure to thrive, mental disorders, or critical illness.44 Hallmark features of RS include hypophosphatemia, hypokalemia, and hypomagnesemia.44 Thiamine deficiency can also be caused by RS as its demand increases dramatically during the transition from starvation to feeding. Thiamine is a cofactor for glucose dependent metabolic pathways. Thiamine deficiency can manifest as neurological abnormalities or oculomotor abnormalities.44 ASPEN has published consensus recommendations for identifying and management of pediatric patients with RS (see Tables 6-19 and 6-20).